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CHAPTER I 
 
INTRODUCTION 
 
Overview of Dopamine Neurotransmission 
 
Dopamine as a neurotransmitter: Discovery 
The sophisticated ability of the nervous system to rapidly convert electrical 
signals into chemical, appropriately integrating excitatory, inhibitory and 
modulatory inputs, enables the brain to control our physiology and behavior. 
Neurotransmitters are chemical transducers propagating intraneuronal electrical 
signals of an action potential interneuronally, thereby forming neurocircuitry that 
enables the brain to function. Modulatory neurotransmitters, such as 
catecholamines, are essential to shaping both the amplitude as well as the 
duration of excitatory and inhibitory neuronal signaling. Dopamine (DA, 3,4-
dihydroxyphenethylamine) is a monoamine neurotransmitter, which contains a 
catechol group connected to an aromatic ring by a two-carbon chain. DA shares 
the common biosynthetic pathway with another catecholamine neurotransmitter, 
norepinephrine (NE) (Figure 1), and initially was considered only as an 
intermediate in its production. The importance of the brain DA system was 
recognized once the studies on Parkinson disease revealed the dependence of 
movement on central DA: the loss of normal motor function was shown to stem 
from the degeneration of DA neurons in substantia nigra pars compacta (SNc) in 
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the midbrain. DA received its neurotransmitter status after seminal work of Avid 
Carlsson and coworkers showing that it is indeed DA, and not NE, which was 
essential for the DOPA-mediated restoration of reserpine-induced movement 
abnormalities (Carlsson et al., 1957). Further research revealed the essential role 
of DA for many brain functions, including motor control, salience, reward, 
learning, memory, attention, and mood.  
 
 
 
 
Figure 1. Dopamine biosynthesis and metabolism. Enzymes are 
labeled in red, and reactants/products are labeled in blue.  
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Early studies on brain DA demonstrated that it was enriched in the basal 
ganglia (Bertler and Rosengren, 1959), highlighting the importance of the brain 
region specificity in DA signaling. In addition, Parkinsonian patients showed 
reduced DA levels in the basal ganglia, linking striatal DA neurotransmission to 
movement (Ehringer and Hornykiewicz, 1960, 1998). Finally, the important role of 
DA in motor control was established when treatment with L-DOPA (L-3,4-
dihydroxyphenylalanine, the immediate DA precursor, allowing to bypass the rate 
limiting step in DA biosynthesis) provided therapeutic effect in patients with 
Parkinson disease (Barbeau, 1962; Birkmayer and Hornykiewicz, 1962; 
Carlsson, 1987). The specificity of the brain region involved suggested that 
unique dopaminergic pathways may play a fundamental role in disease 
pathophysiology.  
Accumulating evidence linking striatal DA tone and motor function served 
a pivotal role in the DA hypothesis of schizophrenia. A pioneering idea of Henri 
Laborit to use chlorpromazine to treat psychotic patients was tested in 1951 by 
John Delay and Pierre Deniker, who confirmed that high doses of this drug calm 
highly agitated schizophrenic or manic depressive patients. Chlorpromazine-
induced extrapyramidal side effects targeted DA-dependent motor system, which 
allowed for the hypothesis that DA neurotransmission may be altered in 
schizophrenia. Indeed, Carlsson and Lindqvist analyzed the action of 
chlorpromazine and haloperidol, another typical antipsychotic with similar 
properties, in the mouse brain. By demonstrating an increased rate of DA 
turnover, they suggested that the drugs acted by blocking DA receptors (1963) 
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(Carlsson and Lindqvist, 1963). This theory was later confirmed by radioactive 
binding (Burt et al., 1975; Seeman et al., 1975). 
 
Overview of the DA neuroanatomy 
Development of fluorescent DA allowed for mapping of the dopaminergic 
pathways in the brain (Dahlstroem and Fuxe, 1964; Fuxe et al., 1965; 
Ungerstedt, 1971). Combining pharmacological approaches with lesion 
techniques, scientists started to tease apart the DA pathways and their unique 
disease implications (Anden, 1970; Anden et al., 1970b; Anden et al., 1970a; 
Anden, 1972). The three most extensive DA pathways include mesolimbic 
(projecting from the VTA to the nucleus accumbens, septum, amygdala, olfactory 
tubercle, and piriform cortex), mesocortical (from the VTA to the prefrontal, 
cingulate, and entorhinal cortices), and nigrostriatal pathway (supplying DA from 
the SNc to the dorsal striatum: nuclei of caudate and putamen) (Figure 2). These 
DA circuits are implicated in a variety of physiological and behavioral processes. 
They are extensively studied to determine each pathway’s individual contribution, 
as well as their intricate interplay in health and disease. Recently, techniques 
such as optogenetics, DREADDs (designer receptors exclusively activated by 
designer drugs), and CLARITY (Clear, Lipid-exchanged, Anatomically Rigid, 
Imaging/immunostaining compatible, Tissue hYdrogel) has tremendously 
advanced our understanding of DA pathways in health and disease (Baik, 2013; 
Lerner et al., 2015; Saunders et al., 2015; Zheng and Rinaman, 2015).  
	   13	  
DA biosynthesis is a two-step process limited to the DA neurons, the 
majority of which originate in mesencephalon (particularly in the SNc and the 
VTA) and diencephalon (predominantly in the hypothalamus), as well as in the 
dopaminergic cells within so-called ultra-short DA systems in the retina and 
olfactory bulb.  	  
 
 
Figure 2. Dopamine pathways in the brain. Shown are the four major 
dopaminergic tracts in the brain: nigrostriatal and mesocorticolimbic systems 
originate in the midbrain in the substantia nigra and the VTA, respectively. The 
nigrostriatal pathway supplies DA to the dorsal striatum (implicated in movement 
disorders). Mesocorticolimbic system projects to the cortical structures (important 
for affect, emotion, and motivation; implicated in schizophrenia). The smaller, 
tuberoinfundibular system originates in the arcuate nucleus of the hypothalamus 
and projects to the pituitary gland (important for the endocrine system). Image 
obtained from cnsforum.com 
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Tyrosine hydroxylase (TH), the rate-limiting enzyme in DA biosynthesis, 
converts amino acid tyrosine into L-DOPA. Tyrosine penetrates the blood brain 
barrier by means of an active transport process, which, considering normal 
dietary consumption of this amino acid, fully saturates TH activity. Therefore, in a 
case of decreased brain dopamine content, administration of supplementary 
tyrosine does not produce a therapeutic effect, in contrast to L-DOPA, which 
increases catecholamine synthesis by penetrating the blood brain barrier and 
bypassing this rate-limiting enzymatic step. L-DOPA is then further synthesized 
into DA by aromatic amino acid decarboxylase (AADC) (Figure 1). Utilizing a 
steep electrical gradient created by ATP-powered proton pumps, DA is then 
packaged into vesicles against its chemical gradient by the vesicular monoamine 
transporter (VMAT) and prepared for synaptic release.  
The integrity of DA neurotransmission depends on the rates of DA 
synthesis and release as well as on the efficiency of extracellular DA clearance. 
For signal termination, many neurotransmitter systems rely on the system of 
enzyme-mediated catabolism. Similarly, both monoamine oxidase (MAO) and 
catecholomethyl transpherase (COMT) aid in the process of signal termination by 
mediating the enzymatic DA catabolism into its metabolites 3-MT, DOPAC, and 
HVA (Figure 1). However, for the catecholaminergic systems, the main method of 
neurotransmitter clearance and, therefore, signal termination, is transporter-
mediated. The first evidence for a transport mechanism for biogenic amines 
dates to the early 1960’s, when Axelrod and colleagues showed accumulation of 
norepinephrine in nerve endings, followed by its stimulated release (Axelrod et 
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al., 1961). Further characterization of the newly discovered mechanism revealed 
that DA undergoes similar process in distinct brain regions (Ross and Renyi, 
1967). It took two decades to clone and categorize the monoamine 
transporters(Kilty et al., 1991; Pacholczyk et al., 1991; Shimada et al., 1991). 
Availability of the cDNAs allowed for extensive investigations of the transport 
mechanism.  
 
Dopamine Transporter 
At the dopaminergic synapse and perisynaptic space, the DA transporter 
(DAT) is an integral membrane protein consisting of 12 transmembrane domains, 
with intracellular N- and C-termini. DAT actively translocates DA from the 
extracellular milieu back into the dopaminergic neurons, efficiently terminating 
DA signaling, and thereby preventing DA spillover to other synapses. Once 
recycled, DA is then repackaged into the vesicles (Giros and Caron, 1993), or 
degraded by MAO. DA recycling is essential for the integrity of synaptic DA 
release: the recycled pool is the main source of DA for the vesicular packaging 
(Giros et al., 1996). For fulfilling its vital functions, DAT is deemed to be the key 
regulator of DA neurotransmission in the brain. Studies in transgenic animal 
models as well as clinical research show that altered expression or function of 
the DAT has significant impact on DA-dependent behaviors and disease. Thus, 
DAT knockout (KO) mice exhibit at least a 100 times slower DA clearance 
compared to control animals, consequentially showing hyperdopaminergic-like 
behaviors, such as extreme hyperactivity, impulsivity, and anxiety in the novel 
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environment. In addition, DAT KO mice demonstrate a substantial reduction in 
the stimulated vesicular DA release, supporting the importance of DAT-mediated 
DA recycling for the intact DA signaling (Giros et al., 1996; Gainetdinov et al., 
1999a; Jones et al., 1999).  
An important contribution to the understanding of DAT function in 
regulating central DA neurotransmission and DA-dependent behaviors is 
provided by the research exploring DAT overexpression. These studies utilized 
amphetamine (AMPH) and cocaine, two psychostimulants adopted for studying 
DAT physiology and proven to be excellent readouts for DA-dependent 
endophenotypes. Cocaine acts by blocking DAT and preventing DAT-mediated 
DA reuptake, which increases extracellular DA concentration (Sulzer et al., 2005; 
Williams and Galli, 2006). AMPH acts to reverse DAT and causes DAT-mediated 
DA efflux (Figure 3).  Mouse model of elevated DAT protein expression (DAT-tg), 
as well as mice with an increased DAT surface expression (Gpr37-/-), exhibit 
exaggerated AMPH-induced hyperlocomotion, with no change in basal 
locomotion (Marazziti et al., 2004; Marazziti et al., 2007; Salahpour et al., 2008). 
In addition, cocaine-induced locomotion is unaltered in the DAT-tg mice, but is 
reduced in the Gpr37-/- mice compared to control animals. In contrast to DAT KO 
mice, animals overexpressing DAT have reduced extracellular DA. Thus, DAT 
expression and function dictate synaptic DA bioavailability as observed in the 
DAT KO and DAT overexpressing mice.  
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Figure 3. Amphetamine-induced DA efflux. Amphetamine (AMPH, red dots) is 
a DAT substrate, which reverses the transport of DA (blue dots), resulting in 
DAT-mediated DA efflux. AMPH also acts as a competitive inhibitor, preventing 
high-affinity DAT-mediated DA reuptake. Once in cytosol, AMPH increases the 
intracellular DA concentration (providing additional substrate for the escalating 
efflux) via activating TH, inhibiting MAO, and depleting DA-containing synaptic 
vesicles by collapsing vesicular pH gradient and disrupting function of the VMAT-
2 (vesicular monoamine transporter-2, which sequesters DA from the cytosol 
creating highly concentrated vesicles, utilizing energy from an ATP-driven inward 
vesicular proton pump). Reviewed by (Sulzer, 2011). 
 
Of interest, the Palmiter group showed that expression of DAT is not 
altered after DA depletion in the neonatal brain (Zhou and Palmiter, 1995), 
suggesting that DAT availability is not dependent on DA levels. Importantly, such 
DA-dependent phenotypes are produced despite multiple compensatory 
developmental adaptations that occur in the transgenic mice in an effort to 
reestablish normal DA neurotransmission. Despite accumulating data, the 
complex dynamic interactions of the molecular players maintaining the integrity of 
DA homeostasis remain incompletely understood. However, available evidence 
DAT 
AMPH 
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suggests that aberrant DA-dependent physiology and behaviors may be caused 
by impaired DAT function.  
Highlighting the importance of DAT in the central DA neurotransmission is 
the fact that DAT is implicated in many DA-related psychiatric disorders, as 
reviewed by (McHugh and Buckley, 2015). DAT polymorphisms were associated 
with treatment-resistant schizophrenia (Bilic et al., 2014) as well as attention 
deficit hyperactivity disorder (ADHD) (Kovtun et al., 2015). De novo genetic 
variants were identified in the DAT of patients with autism spectrum disorder 
(Neale et al., 2012), a pivotal discovery implicating DAT in the pathophysiology of 
autism. This finding provided a great opportunity to study how changes in 
transporter’s structure impact its function and, therefore, alters DA-dependent 
physiology (Hamilton et al., 2013; Bowton et al., 2014; Cartier et al., 2015; 
Hamilton et al., 2015). Despite technical difficulties surrounding the method of 
crystallization of integral membrane proteins, the rapid progress in the field of 
crystallography in the last decade rendered a high-resolution X-ray 
crystallographic structure of the bacterial leucine transporter (LeuT), a 
prokaryotic homolog of the solute carrier 6 (SLC6) gene family that is structurally 
and functionally related to DAT (Yamashita et al., 2005). Based on the crystal 
structure, and utilizing homology modeling to engineer simulation systems that 
include genetic mutations in question, structural biologists employ electron spin 
resonance technique to measure the distances between amino acids and protein 
moieties with high precision. This allows for construction of electronic protein 
models and simulations of DAT and its genetic variants, which are used to 
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understand how intrinsic molecular biomechanics of the transporter effect its 
reuptake function (Hamilton et al., 2013).  
 
Dopamine Transporter Function and Regulation 
As mentioned before, monoamine transporters are homologous, and 
belong to the SLC6 gene family, which constitutes Na+/Cl- -dependent 
neurotransmitter-sodium symporters (Pacholczyk et al., 1991). These 
transporters utilize secondary active transport by coupling neurotransmitter 
reuptake with a sodium gradient across the cellular plasma membrane. Logically, 
cloning of the DAT stemmed immediately from already known sequences of 
norepinephrine and serotonin transporters, revealing a high level of homology 
between the transmembrane domains and the intracellular loops of these 
transporter proteins (Kilty et al., 1991; Shimada et al., 1991). Currently, discovery 
of a genetic variation that changes one of the transporters physiology permits 
scientists to extrapolate the outcomes and assess similar questions for the other 
SLC6 family members, allowing for fruitful findings that advance the transporter 
field as a whole.  
Availability of DAT cDNA allowed for detailed studying of this protein in 
heterologous expression systems, advancing our knowledge of transporter 
biomechanics, pharmacological properties, and means of regulation. Performing 
high affinity DA reuptake, the DAT plays a crucial role in brain DA 
neurotransmission. It is not surprising, therefore, that expression and function of 
DAT are tightly regulated. Two mechanisms can be specified: the long-term one 
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is executed via control over protein biosynthesis and anterograde trafficking, and 
the transient one, which controls the intrinsic properties of the transporter 
function (Blakely and Bauman, 2000). Despite accumulating data regarding DAT 
function, the control of transcription, translation, and anterograde trafficking of the 
transporter remain poorly understood. For example, the most extensively studied 
DAT transcription factor, Nurr1, was shown to be influenced by many kinases 
and phosphatases, but regulatory checkpoints of the DAT gene SLC6A3 
transcription have not yet been elucidated. Similarly, neither the mechanism nor 
the upstream molecular regulators of coordinating Nurr1 function in SLC6A3 
transcription have been identified.  
In contrast to DAT expression and anterograde trafficking, regulation of 
the transporter reuptake properties and intrinsic biomechanics has been 
extensively studied in the last three decades. Many DAT posttranslational 
modifications were shown to regulate transporter function. Naturally occurring 
DAT gene variants coupled with site-directed mutagenesis techniques have 
provided scientists with material to study structure/function relationships. This 
allowed for the identification of important motifs for post-translational 
modifications of DAT, as well as paradigms of both biomechanics of transporters’ 
function and its physiology. It was shown that the DAT requires N-glycosylation in 
the second extracellular loop for trafficking from the Golgi to the cell surface 
(Zahniser and Sorkin, 2009). In addition, utilizing cross-linking reagents and 
FRET imaging techniques in heterologous expression systems, DAT was found 
to form oligomers in the ER, an essential step for the DAT to get shuttled to the 
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plasma membrane (Hastrup et al., 2001; Hastrup et al., 2003; Sorkina et al., 
2003), suggesting a possible mechanism for the DA neuron to control DAT 
surface expression. The integrity of the DAT homodimer was found to be 
sensitive to psychostimulants binding (Hastrup et al., 2003), suggesting that DAT 
oligomerization may play a role in the transporter function. Indeed, a recent study 
showed that the transporter function and its relationship with psychostimulants 
depend on the composition of multimeric proteins: some mutant protomers were 
able to change the function of the wild-type DAT components, as well as the 
entire multimer function (Zhen et al., 2015). Considering the abundance of DAT 
genetic variants in the human population, as well as epidemiologic data linking 
mutant DAT alleles to DA-related mental illnesses, further studies are warranted 
to unravel the detailed mechanism of DAT oligomerization and its physiological 
relevance in vivo.  
Furthermore, DAT phosphorylation was found to regulate transporter 
reuptake and efflux functions, as well as DAT cell surface expression. Cloning of 
the DAT allowed for the proposal of its putative structure, which permitted 
identification of multiple consensus sequences for protein kinase C (PKC) protein 
kinase A (PKA), and calcium/calmodulin-dependent kinase II (CaMKII) in the N- 
and C-terminus and intracellular loops of the transporter (Giros and Caron, 
1993). In vitro studies utilizing chimeras identified discrete DAT domains 
responsible for substrate recognition, translocation, and affinity (Buck and 
Amara, 1994; Giros et al., 1994; Syringas et al., 2000). Further research showed 
that such vital DAT functions as high affinity DA reuptake, psychostimulant-
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mediated DA efflux, transporter cell surface expression, and interaction of DAT 
with other proteins depend on the phosphorylation state of the transporter termini 
(Bauman et al., 2000; Torres et al., 2001; Carneiro et al., 2002; Lee et al., 2004). 
For example, it was shown that CaMKII binding to the DAT C-terminus facilitates 
phosphorylation of the N-terminus, mediating AMPH-induced DA efflux (Fog et 
al., 2006). Of interest, many studies now focus on the importance of electrostatic 
interactions of the DAT N-terminus with the negatively charged PIP2 lipids of the 
plasma membrane, suggesting that the preferred cell surface location of the 
transporter is within the lipid rafts (Adkins et al., 2007; Jones et al., 2012; Gabriel 
et al., 2013; Kovtun et al., 2015). Therefore, both intrinsic transporter function 
and trafficking are tightly regulated by multiple signaling pathways, including 
PKC, mitogen-activated protein kinase (MAPK), and, importantly, insulin-PI3K 
signaling pathway (Torres, 2006). Considering how critical DAT is in regulating 
central DA tone, fine-tuning of the abovementioned signaling pathways is 
expected to have high importance in the integrity of the brain DA 
neurotransmission.  
 
Insulin in the Central Nervous System 
 
In the periphery, insulin signaling is indispensable for the regulation of 
plasma glucose levels. Brain glucose utilization, however, is not insulin 
dependent. Rather, functions of insulin in the brain range from signaling 
peripheral metabolic status to the regulation of reward, development, cognition 
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and others (Schulingkamp et al., 2000; Daws et al., 2011). The notion of insulin 
presence in the brain was controversial until 1967, when the use of sensitive 
radioimmunoassay techniques demonstrated not only that insulin is present in 
the cerebro-spinal fluid (CSF), but also that its CSF levels are increased with 
peripheral insulin infusion (Margolis and Altszuler, 1967). Furthermore, the insulin 
receptor (IR) is widely expressed throughout the brain, including in dopaminergic 
and noradrenergic neurons (Schulingkamp et al., 2000). Despite the ongoing 
debate over the source of brain insulin, the majority of evidence demonstrates 
that the CNS insulin concentration depends on the fidelity of the active and, 
saturable transport of pancreatic insulin at the blood brain barrier (Schwartz et 
al., 1992; Baura et al., 1993; Banks, 2004). Indeed, alterations in the plasma 
insulin concentration are mirrored by the changes in the CSF insulin level 
(Schwartz et al., 1990). Human positron emission tomography (PET) studies 
showed attenuated neuronal activity evoked by a peripheral insulin injection in 
non-diabetic subjects with insulin resistance (Anthony et al., 2006). Such a tight 
correlation between peripheral and central insulin tone supports the fact that 
altered peripheral insulin levels are capable of disrupting insulin signaling in the 
brain. 
 
Insulin regulates brain DA tone via altering DAT function 
Due to the escalating obesity epidemic in the United States, an important 
public health concern is the comorbidity of metabolic disorders and mental 
illness. Mounting evidence suggests that metabolic insulin-PI3K signaling is 
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implicated in the pathogenesis of DA-associated brain dysfunctions, which 
manifest in many mental diseases such as schizophrenia (Emamian et al., 2004; 
Siuta et al., 2010), drug addiction (Mazei-Robison et al., 2011; Neasta et al., 
2011; Chen et al., 2012; Collo et al., 2012), and bipolar disorder (Beaulieu and 
Caron, 2008). One of the crucial regulators of DA tone in the brain, the DAT, is 
shown to heavily rely on the intact insulin-PI3K signaling (Garcia et al., 2005; 
Williams et al., 2007; Lute et al., 2008).  
The pioneering evidence that insulin signaling regulates brain 
catecholamine homeostasis was obtained from rodents pharmacologically 
rendered hypoinsulinemic. These animals demonstrated diminished AMPH-
induced locomotor activity and stereotypy, both of which were reversed by insulin 
treatment (Marshall, 1978). As mentioned earlier (Figure 3), AMPH exerts its 
psychostimulant action via DAT-mediated DA efflux (Fischer and Cho, 1979; 
Sulzer et al., 2005; Sulzer, 2011), therefore its effect is highly dependent on the 
DAT cell surface expression. Alleviation of the decreased AMPH-induced 
behaviors with insulin treatment showed that insulin signaling may affect DAT 
trafficking in vivo. Later studies demonstrate that insulin signaling is required to 
maintain DAT cell surface expression. Thus, pharmacological or diet-induced 
insulin-PI3K pathway inhibition causes clathrin-mediated dynamin-dependent 
DAT endocytosis (Carvelli et al., 2002), leading to a dramatic reduction of DAT 
surface expression and function in vitro (Doolen and Zahniser, 2001; Carvelli et 
al., 2002; Lute et al., 2008), and in vivo (Owens et al., 2005; Williams et al., 2007; 
Sevak et al., 2008b; Sevak et al., 2008a; Speed et al., 2011). Thus, a strong link 
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between metabolic insulin-PI3K signaling and brain DA homeostasis was 
established, and studies began to explore the mechanisms supporting this 
connection.  
 
Insulin Signaling Pathway in the Brain 
In addition to DAT trafficking, insulin has been shown to be the key 
mediator of essential neuronal functions in the brain, including neurotransmitter 
release and reuptake, receptor function, neuronal development and survival (van 
der Heide et al., 2006). PI3K (phosphatidylinositol 3-kinase) lipid kinase and 
protein kinase B (Akt) were found to be the essential molecules regulating insulin 
function in the CNS (Banks et al., 2012). Upon ligand binding and intracellular 
tyrosine autophosphorylation, the insulin receptor activates the scaffold protein 
IRS (insulin receptor substrate) (White, 2002). PI3K, a lipid kinase activated by 
IRS, converts phosphatidyl-inositol into the phosphoinositide phosphates PIP2 
and PIP3, which recruit 3-phosphoinoitide-dependent protein kinase-1 (PDK-1) 
and Akt (protein kinase B) to the plasma membrane (Figure 4). Membrane-
localized Akt is subsequently activated through phosphorylation at two key 
residues – Thr308 by PDK1 (van der Heide et al., 2006)	  and Ser473 by mTORC2 
(mammalian target of rapamycin complex 2)	   (Sarbassov et al., 2005). 
Phosphorylated Akt is involved in multiple cellular functions including 
metabolism, cell stress, cell-cycle, apoptosis, and the regulation of protein 
synthesis and trafficking (Franke, 2008b, a). 
 
	   26	  
 
 
Figure 4. Insulin signaling in the brain.  
 
mTORC2, rapamycin-insensitive complex containing mammalian target of 
rapamycin (mTOR), is ubiquitously expressed and is involved in cell survival, 
growth, and metabolism (Weber and Gutmann, 2012). Rictor (rapamycin-
insensitive companion of TOR) is a component of the mTORC2 complex, the 
scaffolding protein that holds the multiprotein mTORC2 together, allowing for its 
kinase activity. mTORC2 is required for phosphorylation and activation of AGC 
kinase family members (Oh and Jacinto, 2011), including serum/glucocorticoid 
regulated kinase 1 (SGK1), protein kinase C α (PKCα), and Akt (Weber and 
	   	  PROTOR 	  	   	  
	  mTOR 
Rictor 
mTORC2 
DEPTOR 
mLST 
	  
	  PIP2 	  PIP3 	  PIP3 	  
	  
	  
	  	   	   	  
	   	  
IR 
insulin 
Neurodevelopment 
Cell	  survival	   
Receptor	  trafficking 
Neurotransmitter	  release/reuptake 
	  	   	  	  IR
S 
	  	   PI3K 
	   	  AKT PDK
1 
	  	  P P P P 
T	  308 
S	  473 
	  
	  	  
mSIN 
	   27	  
Gutmann, 2012). In the periphery, Akt has been shown to be the key kinase that 
mediates insulin’s glucoregulatory effects (Bae et al., 2003; Kumar et al., 2008). 
Akt is a serine/threonine protein kinase at the center of metabolic insulin 
signaling (Franke, 2008b). In the CNS, Akt activity is indispensible for both 
homeostatic neuroendocrine responses involved in energy balance, peripheral 
fat metabolism, and reproduction (Bruning et al., 2000; Obici et al., 2002; 
Niswender et al., 2003; Koch et al., 2008; Kim et al., 2012), and for higher brain 
functions involved in memory acquisition and storage, reward and salience 
processing, and mood and affect states (Kalkman, 2006; Spencer, 2009; 
Kitagishi et al., 2012; Kanoski et al., 2013; Shi et al., 2014; Machado-Vieira et al., 
2015). Akt activity and substrate selectivity depends on the phosphorylation state 
of its residues Thr308 and Ser473 (Franke, 2008b, a). Despite accumulating 
evidence, molecular and cellular conditions that influence Akt phosphorylation 
are not fully understood. Available data shows that both the extracellular 
environment as well as intracellular context may lead to differential 
phosphorylation of Akt, predicting appropriate substrate selection by this kinase. 
Phosphorylation of Akt at Ser473 requires the rapamycin-insensitive mTORC2 
(Zoncu et al., 2011).  This suggests that mTORC2 is essential in controlling the 
activity as well as the substrate selectivity of the kinase, makingmTORC2/Akt 
signaling one of the main regulators of downstream insulin signaling in the brain.  
 
 
	   28	  
mTORC2/Akt in DA-Associated Neuropsychiatric Disorders 	  
As discussed above, accumulating data support that metabolic kinase Akt 
is implicated in the pathogenesis of DA-associated brain dysfunctions, which 
manifest in many neuropsychiatric diseases. Data from our laboratory and others 
show that Akt signaling regulates brain monoamine homeostasis (Robertson et 
al., 2010; Siuta et al., 2010; Saunders et al., 2014), particularly DA 
neurotransmission (Speed et al., 2011; Dadalko et al., 2015), providing a 
possible molecular link between aberrant Akt signaling and disrupted central DA 
neurotransmission. Important in this context are findings demonstrating that fine 
tuning of Akt activity by its phosphorylation at residues Thr308 and Ser473 plays 
essential role in regulating central DA homeostasis.  
One of the key regulators of Akt function is mTORC2 that renders Akt 
active by phosphorylating its Ser473 residue. Rictor, the rapamycin insensitive 
component of mTORC2, is essential for the complex formation, making 
mTORC2/Rictor necessary for Akt Ser473 phosphorylation (Sarbassov et al., 
2005). Clinical evidence supports a role for mTORC2/Rictor - Akt signaling in 
mental health. Lithium, used to treat bipolar disorder, stimulates phosphorylation 
of Akt at Ser473 (Chalecka-Franaszek and Chuang, 1999). Certain 
antidepressants (Krishnan et al., 2008),	  along with both typical (Emamian et al., 
2004)	   and atypical antipsychotics (Lu and Dwyer, 2005),	   also increase Akt 
Ser473 phosphorylation. Furthermore, findings of diminished Akt Ser473 
phosphorylation and/or its activity in post-mortem brains of patients with 
schizophrenia (Zhao et al., 2006)	   and depression (Karege et al., 2007) 
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strengthen the association between dysregulation of mTORC2/Akt signaling and 
development of DA-associated psychiatric illnesses. Nonetheless, the molecular 
mechanisms linking mTORC2/Rictor - Akt signaling to impairments in central DA 
neurotransmission and behaviors have remained elusive. 
 
mTORC2/Rictor/Akt Signaling Regulates DA Tone: DAT 
Studies conducted in the last decade have unearthed many details in the 
mechanism of DA neurotransmission regulation by the mTORC2/Rictor - Akt 
signaling. As discussed above, one of the key regulators of presynaptic DA is 
DAT.  In vitro studies show that expression of the dominant-negative Akt mutant 
or application of pharmacological Akt inhibitors decreased the cell-surface 
expression of DAT, whereas a constitutively active form of Akt inhibited AMPH-
induced DAT internalization in the human embryonic kidney 293 cells (Garcia et 
al., 2005). Importantly, these DAT trafficking effects were observed within 
minutes after the applied stimulus (Carvelli et al., 2002; Garcia et al., 2005; Lute 
et al., 2008). In addition, it was found that mTORC2/Rictor - Akt signaling plays a 
crucial role in regulating trafficking of catecholamine transporters in the brain: 
norepinephrine transporter (NET) in the cortex (Siuta et al., 2010) and 
hippocampus (Robertson et al., 2010), and DAT in the striatum (Speed et al., 
2011). Both DAT and NET cell surface expression were shown to depend on the 
altered phosphorylation state of the key Akt residues, Thr308 and Ser473. In vitro 
studies using isoform-specific, allosteric Akt inhibitors that block the 
phosphorylation of Akt (Lindsley et al., 2005), suggest that the molecular 
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machinery linking mTORC2/Rictor - Akt signaling and brain DA homeostasis 
relies on Akt phosphorylation and function (Speed et al., 2010). Using AMPH-
induced DA efflux as a biochemical and behavioral readout, our published in vivo 
data reveal that Akt function supports DAT plasma membrane expression 
(Williams et al., 2007; Speed et al., 2011). In contrast with the precise 
pharmacologic or genetic Akt targeting used in the in vitro studies, more 
physiologically relevant approaches were utilized to disrupt Akt activity in these in 
vivo investigations (induction of diabetes type I-like and diabetes type II-like 
states). In the study of Williams and collaborators, streptozotocin-treated and 
therefore insulin-depleted rats showed the reduction of pGSKα, an Akt target, in 
the dorsal striatum (Williams et al., 2007). Speed et al used diet-induced obesity 
in rats to cause brain insulin resistance, thereby reducing pAkt-308 (Speed et al., 
2011). Of interest, most studies show that the reduction in pAkt-308 or the 
complete oblation of Akt activity (pharmacologically or via dominant negative 
mutation) is the underlying cause of reduced surface DAT expression. Limited 
data is available, to date, to tease apart differential Akt phosphorylation and its 
role in the DAT expression and trafficking. In this context, mTORC2/Rictor 
signaling may play a determining factor controlling Akt activity and its substrate 
selectivity. 
 
mTORC2/Rictor/Akt Signaling Regulates DA Tone: Tyrosine Hydroxylase 
Another crucial regulator of presynaptic DA tone is tyrosine hydroxylase 
(TH), the rate-limiting enzyme in DA biosynthesis. TH activity is essential for the 
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integrity of the DA system, as shown by the Parkinson’s disease research 
(Haavik and Toska, 1998; Tabrez et al., 2012), and in studies employing TH 
inhibitors (Moore et al., 1987; Goldstein and Lieberman, 1992). Missense 
mutations in the TH gene are associated with severe infantile Parkinsonism 
(Bademci et al., 2012). Mice that lack TH in the DA neurons (deemed DA 
deficient mice) are not able to sustain feeding behavior and die early after birth 
(Zhou and Palmiter, 1995). Furthermore, TH KO mice are embryonic lethal 
(Thomas et al., 1995). These data highlight the importance of the TH in general 
and within DA neurons in particular. In this context, intriguing is the data showing 
that mTORC2/Akt pathway is implicated in growth and survival of TH-expressing 
DA neurons. In vitro data shows that stimulation of the upstream kinases, RTK 
and PI3K, promotes DA neuron growth and survival, and conversely, inhibition of 
RTK/PI3K interferes with these processes (Kim et al., 2004; Terada et al., 2014). 
Furthermore, in vivo studies which inhibit or enhance Akt signaling in SNc and 
VTA show that the DA neuron soma size, the integrity of DA innervation, and the 
levels of DA and its metabolites in the midbrain and target areas are dependent 
on the fidelity of mTORC2/Rictor signaling and correlate with Akt phosphorylation 
(Ries et al., 2006; Russo et al., 2007; Ries et al., 2009).  
In addition to influencing the morphological properties of TH-expressing 
neurons, mTORC2/Rictor - Akt signaling was proposed to modulate TH function. 
The function of TH is regulated by transcriptional and post-translational 
mechanisms, including protein phosphorylation. Seminal finding by Morgenroth 
et al showed that cAMP-dependent protein kinase activated TH launched a 
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search for TH phosphorylation sites (Morgenroth et al., 1975). Four major TH 
phosphorylation sites were later characterized: Ser-8, Ser-19, Ser-31, and Ser-40 
(Haycock, 1990). In vitro and ex vivo studies found a few kinases and 
phosphatases regulating TH activity, including PKA, PKG, PKC, PP2A (Ser-40); 
ERK1/2, PP2A (Ser-31); CaMKII, PP2A (Ser-19) (Dunkley et al., 2004). Ser-31 
phosphorylation is shown to be co-variant with DA tissue content in vivo 
(Salvatore et al., 2009). Furthermore, Ser-31 phosphorylation is implicated in DA 
biosynthesis, especially in somatodendritic dopaminergic regions such as the 
SNc and VTA (Salvatore and Pruett, 2012).  
To date, no evidence suggests that mTORC2/Akt activity directly affects 
TH function at either the transcriptional or post-translational level. However, 
upstream activators of mTORC2/Akt signaling were shown to enhance DA 
release in PC12 cells (Amino et al., 2002), and in striatal brain slices (Goggi et 
al., 2003). It is possible that the decreased AMPH-induced DAT-mediated DA 
efflux observed in rodent models with perturbed mTORC2/rictor-Akt signaling 
(Dadalko et al., 2015) stems from the impaired TH function since inhibition of TH 
leads to a reduction in psychostimulant-induced DA release (Butcher et al., 1988; 
Thomas et al., 2008). This may be because the newly synthesized pool of DA is 
essential for the AMPH-induced increase in extracellular DA (Butcher et al., 
1988; Thomas et al., 2008). In light of recent evidence showing that DA 
biosynthesis may be autonomously regulated between somatodendritic and 
terminal field compartments (Salvatore and Pruett, 2012), further investigations 
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carefully discriminating between brain regions and evaluating if mTORC2/Akt 
signaling impacts TH activity in the brain region-specific manner are necessary.  	  
mTORC2/Rictor/Akt Signaling Regulates DA Tone: DA Receptors 
Dopamine Receptors Neurophysiology: anatomy and overview 
The multitude of physiological functions controlled by DA in the central 
nervous system is mediated by the DA receptors. DA receptors belong to the G 
protein-coupled receptor (GPCR) superfamily, and have canonical seven-
transmembrane structure. Binding of DA initiates a conformational change in the 
receptor so that it activates a G protein or follows a non-canonical G-protein 
independent mechanism. This in turn generates second-messenger signaling 
cascades, participating in regulation of ion channels, cell excitability, 
posttranslational protein modifications, control of translational mechanisms, and 
many others, as reviewed by (Beaulieu et al., 2015). The signals downstream DA 
receptors are often found overlapping and converging; however, each receptor 
has its unique pharmacologic properties and expression. Specificity of action is 
dependent on the cell types in which a particular receptor is expressed, the 
location of the receptors on these cells (soma, proximal or distal dendrites, 
dendritic spines or shafts, or presynaptic terminals), and the interactions with 
other receptors and signaling systems. DA receptors are ubiquitous throughout 
the brain, modulating control over such functions as movement, reward, affect, 
attention, feeding, olfaction, vision, cognitive function, hormonal and sleep 
regulation.  
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 Dopamine receptors are divided into two groups. The D1 family consists of 
D1 and D5 receptors, which are coupled to Gs or Golf, which stimulate the 
production of cAMP turning on the PKA signaling cascade. D2, D3, and D4 
receptors belong to D2 family, and signal through Gi/Go by inhibiting cAMP 
production. As discussed above, the rates of DA synthesis, release, and 
recycling determine the presynaptic component of DA signaling fidelity. 
Interestingly, seminal work by Carlsson and Lindqvist allowed for the postulation 
of a receptor-mediated feedback mechanism to control the rate of DA synthesis 
and turnover (Carlsson and Lindqvist, 1963). Further investigations discovered 
DA autoreceptors, located on the DA neurons and orchestrating the presynaptic 
DA tone by responding to the DA concentration in the extracellular milieu. DA 
autoreceptors (D2-short) were found to be alternatively spliced D2 DA receptor 
variants, which differ from the postsynaptic ones by lacking 29 amino acids in 
their third intracellular loop. Postsynaptic D2 receptors, or D2-long receptors, were 
found to have distinct physiological, signaling, and pharmacological properties 
from their D2-short counterparts.  
Dopamine Receptors Neurophysiology: Signaling 
Until a decade ago, the prevailing dogma was that DA receptors signal 
exclusively through G-protein dependent mechanisms. By regulating cAMP 
levels, DA receptors were shown to control DARPP-32, DA and cAMP-regulated 
neuronal phosphoprotein (also known as protein phosphatase 1 regulatory 
subunit 1B, PPP1R1B), which is a negative regulator of protein phosphatase 1 
(PP1). DARPP-32 plays an essential role in integrating signals from a number of 
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behaviorally important neurotransmitters and neuromodulators that target the 
striatum (Yger and Girault, 2011). DA neurotransmission and DA-dependent 
behaviors rely on DARPP-32 signaling, which is highly specific to the neuronal 
population where it is expressed.	   For example, ablation of DARPP-32 in D1 
receptor expressing striatonigral medium spiny neurons (MSNs) decreased basal 
and cocaine-induced locomotion and abolished dyskinetic behaviors in response 
to the Parkinson's disease drug L-DOPA, whereas the loss of DARPP-32 in 
striatopallidal D2 expressing MSNs produced a robust increase in locomotor 
activity and a strongly reduced cataleptic response to the antipsychotic drug 
haloperidol (Bateup et al., 2010). DARPP-32 is also shown to regulate DA 
receptor-mediated control over transcriptional process: a signaling cascade 
downstream of PP1, where phosphorylation of mTORC1 and rpS6 influences 
CAP-dependent mRNA translation (Santini et al., 2009; Santini et al., 2010; 
Valjent et al., 2011; Santini et al., 2012; Bonito-Oliva et al., 2013).  
In the last decade, our knowledge of the repertoire of DA receptor 
signaling has grown exponentially. Thus, it was shown that DA receptors 
biological effects could be accomplished via cAMP-independent, non-canonical 
signaling pathways. Such alternative signaling includes, but is not limited to, 
transactivation of BDNF receptors (Swift et al., 2011), internalization of Ca2+ 
channels (Kisilevsky et al., 2008; Kisilevsky and Zamponi, 2008), and heteromer 
formation and alternative coupling to Gαq to mediate IP3 signaling (Hazelwood et 
al., 2008; Blom et al., 2012; Medvedev et al., 2013; Perreault et al., 2014). 
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D2  Dopamine Receptors: Neurophysiology and Function 
Of special interest here is the D2R. The diversity of downstream 
mechanisms activated by D2R supports its key role in the regulation of the DA 
neurotransmission, both pre- and post-synaptically. Presynaptically, D2R plays a 
pivotal role in the regulation of the DAT trafficking and function through 
phosphorylation of ERK1/2 (Meiergerd et al., 1993; Batchelor and Schenk, 1998; 
Dickinson et al., 1999; Bolan et al., 2007; Lee et al., 2009). In addition, D2R 
regulates de novo DA synthesis (Wolf and Roth, 1990; De Mei et al., 2009). 
Postsynaptically, D2R is indispensable for DA signal transduction, making it a key 
target in pharmacological treatment of DA-dependent neuropsychiatric disorders. 
To date, D2R antagonism is one of the unequivocally efficacious therapeutic 
strategies for schizophrenia, indicating a critical role of D2R signaling in this 
devastating disease (Howes and Kapur, 2009). Accumulating data support the 
importance of brain region segregation when studying multiple pathways 
activated by the D2R, which have been shown to depend on various molecular 
contexts.  
In addition to the well-known Gαi/o-mediated cAMP/PKA/DARPP-32 
pathway, D2R has been shown to activate a multitude of signaling cascades. 
Thus, D2R couple to the Gβγ subunits to regulate the PLC signaling pathway 
(Hernandez-Lopez et al., 2000), the activity of L- and N-type Ca2+ channels (Yan 
et al., 1997), as well as G-protein coupled inwardly rectifying potassium 
channels, or GIRKs (Kuzhikandathil et al., 1998).  
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mTORC2/Rictor/Akt signaling through D2  Dopamine Receptors 
Particularly interesting is the accumulating data supporting G-protein 
independent signaling of the D2R by complex formation with β-arrestin2 (βArr2), 
PP2A, and Akt (Beaulieu et al., 2004), reviewed in (Beaulieu et al., 2011). βArr2 
is a well-known regulator of GPCR function. βArr2 plays a crucial role in GPCR 
signal termination through receptor desensitization and G-protein uncoupling, 
followed by βArr2-mediated clathrin-dependent endocytosis (Lohse et al., 1990; 
Ferguson et al., 1996). Furthermore, βArr2 was found to act as a scaffold for 
kinases and phosphatases, forming multiprotein complexes that influence many 
intracellular signaling cascades (Luttrell et al., 1999; Luttrell and Gesty-Palmer, 
2010). 
The formation of βArr2 - Akt - PP2A complex in response to D2R activation 
was shown to inactivate PI3K/Akt signaling and cause an increase in GSK3 
activity. GSK3 dysfunction has been suggested as a potential pathway for the 
development of DA-related neuropsychiatric diseases, as reviewed in (Beaulieu 
et al., 2011). Lithium, which is used to alleviate manic symptoms of bipolar 
disorder as well as schizophrenia and schizoaffective psychoses, has been 
shown to activate Akt and enhance inhibitory phosphorylation of GSK3 in the 
rodent models of aforementioned DA-related disorders (Beaulieu et al., 2004; 
Emamian et al., 2004; Li et al., 2007).  The key finding demonstrating the direct 
contribution of DA in the regulation of Akt/GSK3 signaling is the study in DAT-KO 
mice utilizing inhibition of de novo DA synthesis by the irreversible TH inhibitor, 
α-methyl-para-tyrosine (Beaulieu et al., 2004). The virtual absence of striatal DA 
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upon TH inhibition enhanced Akt activity and increased phosphorylation of GSK3 
in the DAT-KO mice. Similar biochemical changes were observed with 
application of D2R blockade or administration of lithium salts, suggesting a major 
role for D2R – Akt – GSK3 signaling in DA-related neuropsychiatric disorders.  
 
Introduction to the neuronal Rictor KO mouse model 	  
Out of the three Akt isoforms identified, Akt1 genetic variants have been 
associated with the etiology of schizophrenia (Emamian et al., 2004). For 
example, Akt1 null mice demonstrate enhanced sensitivity to psychostimulant 
effects of dopaminergic and noradrenergic agents (Emamian et al., 2004; Lai et 
al., 2006).	  Decreases in Akt1 mRNA, protein, and activity levels were found in the 
brains of schizophrenia patients (Thiselton et al., 2008). It is important to 
remember that Akt activity depends on its two key phosphorylation sites: Thr308 
and Ser743, both of which control Akt conformation, interaction with other 
proteins, as well as its substrate selectivity (Franke, 2008a, b). Clinical evidence 
supports a role for mTORC2/Akt signaling in DA-dependent mental illnesses. 
Lithium, used to treat bipolar disorder, stimulates phosphorylation of Akt at 
Ser473 (Chalecka-Franaszek and Chuang, 1999). Certain antidepressants 
(Krishnan et al., 2008), along with both typical (Emamian et al., 2004) and 
atypical antipsychotics (Lu and Dwyer, 2005), also increase Akt Ser473 
phosphorylation. Furthermore, findings of diminished Akt Ser473 phosphorylation 
and/or its activity in post-mortem brains of patients with schizophrenia (Zhao et 
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al., 2006) and depression (Karege et al., 2007) strengthen the association 
between dysregulation of mTORC2/Akt signaling and development of DA-
associated psychiatric illnesses. Nonetheless, the molecular mechanisms linking 
mTORC2/Akt to impairments in DA neurotransmission and behaviors have been 
elusive.  
To engineer a mouse model with aberrant mTORC2/Akt signaling, we 
used the Cre-LoxP mediated genetic recombination technology, which allows for 
the selective deletion of genes along tissue specific promoters. The Nestin-Cre 
promoter was chosen for its ability to delete the gene of interest in the entire 
brain.  Deletion of a gene along a Nestin-Cre promoter generates viable mice for 
the Rictor gene, but not for the PDK1 gene (Oishi et al., 2009). As a result of this 
genetic strategy, the Rictor/Nestin-Cre transgenic cross, or nRictor KO mice, 
have severely depleted brain Akt Ser473 phosphorylation. This provides a great 
model in which to study how aberrant mTORC2/Akt signaling in the brain impacts 
central DA homeostasis.  
A previously published study in the nRictor KO mouse model 
demonstrated severe alterations in cortical DA tone (Siuta et al., 2010). Disrupted 
mTORC2/Akt signaling and decreased brain Akt Ser473 phosphorylation led to 
cortical hypodopaminergia and pre-pulse inhibition deficits. These characteristic 
schizophrenia-associated endophenotypes are thought to stem from altered 
cortical and striatal DA neurotransmission (Braff et al., 2001; Emamian et al., 
2004; Howes and Kapur, 2009; Keri et al., 2009). Striatal DA bioavailability is 
fundamental in the development of schizophrenia (Davis et al., 1991b; Howes 
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and Kapur, 2009), and is increased during prodromal and psychotic states 
(Howes and Kapur, 2009). Such elevated DA levels correlate with the positive 
symptoms of the disease, and antidopaminergic drugs, such as a D2R blocker 
typical antipsychotic haloperidol, are effective in reducing these symptoms in 
most patients (Abi-Dargham et al., 2000).  
The specific aims of this thesis will focus on exploration of impairments in 
nigro-striatal DA neurotransmission as they occur under the influence of aberrant 
mTOR2/Akt signaling. Specific attention will be given to such DA homeostasis 
regulators as DAT, TH, and D2R, as well as DA-regulated stiatum-dependent 
behaviors. In addition to the nRictor KO mouse, a TH-Rictor KO transgenic line 
will be introduced. This mouse model, with disrupted mTORC2/Akt signaling in 
the TH expressing cells, will allow to hone in on the mTORC2/Akt function within 
pre-synaptic monoaminergic pathways. Finally, using a viral intervention 
technique, we will disrupt mTORC2/Akt function in the dorsal striatum, targeting 
the brain region of interest to assess DA-related behaviors, as well as eliminate 
possible confounding developmental compensations of transgenic mouse 
models.  
Thus, our Specific Aims are: 
I) To test the hypothesis that impairment in brain mTORC2/Rictor 
signaling disrupts central DA tone and to assess the key elements 
responsible for aberrant striatal DA homeostasis in the nRictor KO 
mice. 
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II) To determine whether aberrant brain mTORC2/Rictor signaling alters 
DA (subcortical) related behaviors.  
 
III) To assess which neuronal populations or subcortical loci are 
vulnerable to disruption of mTORC2/Rictor signaling in producing 
biochemical and behavioral DA-dependent phenotypes.  	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CHAPTER II 
 
mTORC2/RICTOR SIGNALING DISRUPTS DOPAMINE-DEPENDENT 
BEHAVIORS VIA DEFECTS IN STRIATAL DOPAMINE 
NEUROTRANSMISSION* 
 
Abstract 	  
Disrupted neuronal protein kinase B (Akt) signaling has been associated with 
dopamine (DA) related neuropsychiatric disorders, including schizophrenia, a 
devastating mental illness. We hypothesize that proper DA neurotransmission is, 
therefore, dependent upon intact neuronal Akt function. Akt is activated by 
phosphorylation of two key residues, Thr308 and Ser473. Blunted Akt 
phosphorylation at Ser473 (pAkt-473) has been observed in lymphocytes and 
post-mortem brains of schizophrenia patients, and psychosis-prone normal 
individuals. Mammalian target of rapamycin (mTOR) complex 2 (mTORC2) is a 
multiprotein complex which is responsible for phosphorylation of Akt at Ser473 
(pAkt-473). We demonstrate that mice with disrupted mTORC2 signaling in brain 
exhibit altered striatal DA-dependent behaviors, such as increased basal 
locomotion, stereotypic counts and exaggerated response to the psychomotor 
effects of amphetamine (AMPH). Combining in vivo and ex vivo pharmacological, 
electrophysiological, and biochemical techniques we demonstrate that the 
* The work presented in this chapter is published as Olga I. Dadalko, Michael Siuta, Amanda 
Poe, Kevin Erreger, Heinrich J.G. Matthies, Kevin Niswender, Aurelio Galli (J. Neuroscience; 
2015 Jun 10;35(23):8843-54) 
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changes in striatal DA neurotransmission and associated behaviors are caused, 
at least in part, by elevated D2 DA receptor (D2R) expression and upregulated 
ERK1/2 activation. Haloperidol, a typical antipsychotic and D2R blocker, reduced 
AMPH hypersensitivity and elevated pERK1/2 to the levels of control animals. By 
viral gene delivery, we downregulated mTORC2 solely in the dorsal striatum of 
adult wild-type mice, demonstrating that striatal mTORC2 regulates AMPH 
stimulated behaviors. Our findings implicate mTORC2 signaling as a novel 
pathway regulating striatal DA tone and D2R signaling. 
 
Introduction 
 
     Impaired brain dopamine (DA) homeostasis is strongly implicated in 
neuropsychiatric disorders such as schizophrenia and psychostimulant abuse 
(Narendran and Martinez, 2008; Howes and Kapur, 2009; Espana and Jones, 
2013; Nestler, 2013).  Evidence from studies in animal models supports the key 
role of insulin resistance in aberrant striatal DA signaling (Wang et al., 2001; 
Wang et al., 2002; Johnson and Kenny, 2010; Daws et al., 2011; Niswender et 
al., 2011; Speed et al., 2011) 
 In the CNS, insulin signaling regulates reward, development, and cognition 
(Schulingkamp et al., 2000; Daws et al., 2011). Importantly, insulin activates 
intracellular kinases including Akt (van der Heide et al., 2006). Three isoforms of 
Akt have been identified and their brain expression characterized. Seminal 
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findings revealed a strong correlation between genetic variants of Akt1 and 
schizophrenia (Emamian et al., 2004; Nicodemus et al., 2008; Nicodemus et al., 
2010; Tan et al., 2012), a DA-associated neuropsychiatric disorder (Howes and 
Kapur, 2009). Thus, it has been proposed that brain DA dysfunction could stem 
from altered Akt signaling (Niswender et al., 2011).  Recently, we and others 
have shown that aberrant brain Akt function stemming from either an obesogenic 
diet or diabetes results in impaired striatal DA homeostasis contributing to DA-
dependent behaviors (Williams et al., 2007; Speed et al., 2010). However, the 
molecular mechanisms linking Akt dysfunction with altered DA neurotransmission 
have yet to be established.  
 Mammalian target of rapamycin (mTOR) complex 2 (mTORC2) is a 
multiprotein complex that is a critical regulator of cell growth and metabolism. 
mTORC2 contains Rictor, mSIN1, mLST8, and mTOR. Akt, along with other 
kinases, is a primary substrate of mTORC2 which is responsible for 
phosphorylation of Akt at Ser473 (pAkt-473), one of two key phosphorylation 
sites. To study how aberrant mTORC2 signaling influences central DA 
neurotransmission, we used Cre-LoxP technology to disrupt the mTORC2 
complex by neuronal ablation of the Rictor protein (nRictor KO mouse model; 
(Shiota et al., 2006; Siuta et al., 2010)). We show that impaired mTORC2/Akt 
signaling alters striatal DA tone, increases basal and AMPH-induced locomotion, 
and stereotypic counts. These behaviors, traditionally associated with elevated 
striatal DA signaling (Sharp et al., 1987; Rebec, 2006; Kreitzer and Malenka, 
2008), were associated instead with diminished striatal DA bioavailability. 
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Furthermore, viral-mediated recombination specifically in dorsal striatum 
supports the hypothesis that this brain region has a major role in mediating DA-
driven behavioral dysfunction in response to aberrant mTORC2 signaling and 
possibly Akt Ser473 phosphorylation. 
 
Results 
 
Neuronal deletion of Rictor results in impaired Akt Ser473 phosphorylation and 
increased DA transporter expression and function in the dorsal striatum: Akt is a 
serine/threonine protein kinase, whose activity and substrate selectivity is 
regulated by phosphorylation at two key residues: Thr308 by phosphoinositide-
dependent kinase-1, PDK1, and Ser473 by mTORC2. Rictor – rapamycin 
insensitive companion of mTOR – is the scaffolding protein that maintains 
mTORC2 integrity, allowing for its kinase activity. nRictor KO mice were 
generated by crossing floxed Rictor animals with nestin-Cre transgenic mice, as 
previously described (Siuta et al., 2010). We have shown that nRictor KO mice 
lack both rictor mRNA and protein expression in a gene-dosage dependent 
manner within the brain (Siuta et al., 2010). Figure 5A (inset) reveals a lack of 
Akt Ser473 phosphorylation in the dorsal striatum of the nRictor KO animals, 
whereas total Akt is unchanged. Our laboratory and others have previously 
shown that Akt function regulates DA transporter (DAT) trafficking (Doolen and 
Zahniser, 2001; Carvelli et al., 2002; Garcia et al., 2005; Franke, 2008b; Lute et 
al., 2008; Speed et al., 2010) and, thereby, DA-related behaviors (Williams et al., 
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2007; Speed et al., 2011; Owens et al., 2012). Thus, to understand the role of 
mTORC2/Akt signaling in DA neurotransmission, we first evaluated DAT surface 
and total expression in the dorsal striatum of nRictor KO and control (CTR)   
 
Figure 5. DAT expression and function is increased in the dorsal striatum 
of the nRictor KO mouse. A) Representative immunoblots of surface and total 
protein fractions probed with a selective anti-DAT antibody or with an anti-Na-K 
ATPase antibody to serve as a loading control. TH, a cytosolic protein was 
detected in the total fraction but not in the biotinylated fraction. Inset: 
representative immunoblot of pAkt-473 in the dorsal striatum of nRictor KO mice 
and CTR animals. B) Quantitation of the optical density of DAT surface fraction 
normalized to CTR. C) Quantitation of the optical density of the total protein 
fraction normalized to CTR. D) [3H]-DA uptake in anatomically paired striatal 
slices obtained from CTR and nRictor KO mice expressed as a percent of 
control.  
 
animals. Using biotinylation (representative immunoblots are shown in Fig. 5A), 
we observed that defects in mTORC2 signaling lead to increased DAT plasma 
membrane expression (Fig.5B; t(12)=3.3, p≤0.01, paired t-test) and elevated total 
expression of DAT (Fig. 5C; t(15)=3.1, p≤0.01, paired t-test). The absence of the 
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cytosolic protein tyrosine hydroxylase (TH) in the surface fraction indicates the 
integrity of the experimental preparation while Na/K ATPase serves as a loading 
control (Fig. 5A). We next sought to determine whether augmented total and 
membrane DAT expression in nRictor KO mice leads to an increase in DAT 
function. To quantify DAT function, we assessed [3H]-DA uptake in acute striatal 
slices. Consistent with the strong increase in DAT protein expression, nRictor KO 
mice exhibited significantly higher [3H]-DA uptake (Fig. 5D; t(16)=2.9, p≤0.01, 
paired t-test).  
 nRictor KO mice exhibit increased novelty-induced locomotion, stereotypic 
counts, and exaggerated response to AMPH: DA reuptake by the DAT is the 
primary mechanism of terminating DA transmission in the dorsal striatum, 
shaping the duration and amplitude of DA signaling (Kristensen et al., 2011). DA 
neurotransmission is essential for initiation and organization of motor function 
(Birkmayer and Hornykiewicz, 1961; Hornykiewicz, 1966; Cotzias et al., 1967; 
Fischer and Heller, 1967; Ungerstedt, 1968; Ungerstedt and Pycock, 1974; 
Goldstein et al., 1975; Langston and Ballard, 1983), and therefore DAT function 
is critical in DA-dependent behaviors, such as locomotor activity. Thus, we 
determined whether changes in DAT expression and function translate to altered 
DA dependent behaviors in nRictor KO mice.  
 First, we examined basal locomotion. After five days of handling (see 
methods), animals were placed in open field chambers and allowed to freely 
explore. Locomotor activity was measured as distance travelled in five-minute 
bins. Compared to CTR, nRictor KO mice exhibit a dramatic and stable increase 
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in horizontal locomotion (n=12, two-way ANOVA, effect of genotype F(1,528)=1492, 
p<0.0001; followed by Bonferroni post-hoc test ***p<0.001 (Fig. 6A)).  
Furthermore, stereotypic counts (stereotypic episodes counted in beam breaks 
within a small 4-beam box) in nRictor KO mice are significantly elevated with 
respect to CTR animals (n=10, two-way ANOVA, effect of genotype 
F(1,648)=523.8, p<0.0001; followed by Bonferroni post-hoc test **p<0.01, 
***p<0.001 (Fig. 6B)).   These data are consistent with the notion that impaired 
striatal DA neurotransmission contributes to aberrant “stereotypic behaviors” 
(Kelly et al., 1975; Andrews et al., 1982; Carr and White, 1984; Porrino et al., 
1984; Sharp et al., 1987). Mice heterozygous for rictor deletion did not show 
alterations in locomotor activity or stereotypic counts (data not shown), 
demonstrating that nestin-Cre transgene has no effect on these DA associated 
behaviors.  Importantly, this also strongly suggests that the full blockade of 
mTORC2 signaling is necessary to induce the phenotype observed in the nRictor 
KO.  
 AMPH exerts its action mainly via DAT, causing non-vesicular DAT-mediated 
DA efflux (Kahlig et al., 2005; Sulzer et al., 2005). The observed increase in DAT 
expression in the dorsal striatum of the nRictor KO mice allowed us to 
hypothesize that AMPH would cause exaggerated behavioral responses in 
nRictor KO animals. Consistent with this hypothesis, mice that overexpress DAT 
(DAT-tg), as well as animals with an increased DAT surface expression (Gpr37-/-
) exhibit exaggerated AMPH-induced hyperlocomotion (Marazziti et al., 2004; 
Salahpour et al., 2008). In order to evaluate changes in the locomotor response 
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caused by AMPH in nRictor KO mice, a 6-day long habituation protocol (see 
methods) was empirically used to decrease the basal locomotion of the nRictor 
KO to the level of CTR mice. On the test day (day 7), an initial saline injection  
 
Figure 6. Neuronal deletion of Rictor results in novelty-induced 
hyperactivity, increased stereotypic counts, and exaggerated locomotor 
response to AMPH. A) Horizontal locomotion measured in open field chambers 
in 5-min intervals. Shown is the distance traveled in cm. B) Stereotypic counts 
binned in 5-min intervals. C) AMPH (i.p., 2mg/kg) stimulated locomotor activity 
binned in 15-min intervals. Both CTR and KO mice were habituated to achieve 
non-significant differences in basal locomotor activity before AMPH injection. 
Data represent distance traveled in cm. D) 30 minutes after 2mg/kg AMPH i.p., 
animals were sacrificed, and tissue content of AMPH was measured by HPLC in 
striatal homogenates. 
 
was followed by a 2h period in the chamber, a sufficient time for all animals to 
reach comparable baseline locomotion. AMPH (2mg/kg) was then administered 
i.p. (time 0) and horizontal locomotion was recorded in five-minute bins for the 
next two hours. nRictor KO animals demonstrate exaggerated psychomotor 
response to AMPH, with locomotor activity markedly higher than that of CTR 
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animals (n=10, two-way ANOVA, effect of genotype F(1,198)=71.15, p<0.0001; 
followed by Bonferroni post-hoc test *p<0.05, **p<0.01, ***p<0.001 (Fig. 6C)).  
The AMPH tissue content in the dorsal striatum of the nRictor KO mouse is 
comparable to the CTR animals (Fig. 6D; t(4)=2.7, p>0.05, unpaired t-test),  and, 
importantly, is clearly not elevated relative to CTR, indicating that AMPH 
transport across the blood brain barrier is not altered by Rictor deletion. 
 DAT expression and cellular distribution is precisely regulated, and 
alterations in DAT availability could contribute to DA dysfunction and to the 
pathophysiology of neuropsychiatric disorders. However, clinical studies have not 
been consistent on this issue, showing increased, decreased, or no change in 
striatal DAT availability in patients with schizophrenia (Brunelin et al., 2013). We 
have shown that decreased brain mTORC2 signaling also results in deficits in 
pre-pulse inhibition (Siuta et al., 2010). Here, we demonstrate that elevated 
striatal surface and total DAT support AMPH hypersensitivity. Psychostimulants, 
including AMPH, cause changes in behavior by elevating striatal DA 
bioavailability (Rebec, 2006). Thus, our data suggest elevated DA tone in the 
dorsal striatum of nRictor KO mice. Therefore, our next goal was to determine 
the neuronal adaptation caused by mTORC2 signaling within the DA network. 
nRictor KO mice exhibit reduced AMPH-induced DA release, tissue DA content, 
and TH phosphorylation: Basal hyperlocomotion and exaggerated locomotor 
response to AMPH are phenotypes suggestive of striatal DA hyperfunction 
(Bardo et al., 1990; Rebec, 2006). To further test this, we evaluated AMPH-
induced DA release in the dorsal striatum of nRictor KO mice by in vivo 
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microdialysis and ex vivo chronoamperometry. The nRictor KO mouse has 
reduced brain size (Siuta et al., 2010) consistent with the phenotype of the Akt3 
KO mouse (Easton et al., 2005). Thus, we empirically defined the stereotactic 
coordinates to ensure accurate and parallel placement of the probe in the nRictor 
KO and CTR animals. 18-24 hours after mice underwent guide cannula 
placement, microdialysis probes were inserted into the dorsal striatum of nRictor 
KO and CTR mice. Dialysate samples were collected in 20-minute intervals, and 
analyzed by HPLC for monoamines and metabolites content. After establishing a 
stable baseline, AMPH was administered (2mg/kg i.p.). AMPH-induced DA 
release was significantly reduced in the dorsal striatum of nRictor KO mice 
relative to CTR (n=2, two-way ANOVA, effect of genotype F(1,12)=13.8, p<0.01; 
followed by Bonferroni post-hoc test *p<0.05 (Fig. 7A)).  
 To confirm this reduction in AMPH-induced DA efflux, we employed ex vivo 
chronoamperometry to measure AMPH-induced DA release directly from striatal 
slices. Coronal slices with dorsal striatum were recovered in 28°C oxygenated 
aCSF for a minimum of one hour prior to recording. The carbon fiber electrode 
was angularly deepened into the dorso-lateral portion of the striatum (same 
locale as microdialysis). AMPH (10 µM) was bath applied after 30 minutes of 
baseline recordings. In agreement with the microdialysis data, AMPH-induced 
DA release was significantly reduced in the striatal tissue of the nRictor KO 
compared to CTR animals (n=6, two-way ANOVA, effect of genotype 
F(1,410)=106.4, p<0.0001; followed by Bonferroni post-hoc test *p<0.05, **p<0.01, 
***p<0.001 (Fig. 7B)). 
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Figure 7. nRictor KO exhibit reduced AMPH-induced DA release, tissue DA 
content, and TH phosphorylation. A) Time course of extracellular DA 
concentration as measured by microdialysis coupled with HPLC from the dorsal 
striatum of CTR and nRictor KO mice after i.p. administration of AMPH (2mg/kg). 
Results are shown as percent of baseline in 20-min intervals. B) AMPH-induced 
(10 µM) DA release measured by oxidation currents from striatal slices reported 
as µM DA release. C) Top, pTH-Ser31 and TH representative immunoblots 
obtained from striatal tissue. Bottom, quantification of the ratio of pTH-Ser31 to 
total TH expressed as a percent of CTR. D) DA tissue content, its precursor 
tyrosine, and its metabolites DOPAC and HVA as measured by HPLC in striatal 
homogenates. 
 
 It is possible that the observed decrease in AMPH-induced DA efflux stems 
from impaired function of TH, the rate limiting enzyme for DA synthesis. Indeed, it 
has been shown that TH inhibition leads to a reduction in psychostimulant-
induced DA release, confirming that the newly synthesized pool of DA is 
essential for AMPH induced DA efflux (Butcher et al., 1988; Thomas et al., 2008). 
TH conformation and activity is regulated by four phosphorylation sites.  Ser31 is 
	   53	  
the key residue whose phosphorylation correlates with TH activity in vivo 
(Salvatore et al., 2009; Damanhuri et al., 2012; Salvatore and Pruett, 2012). 
Further, it has been shown that DA levels also correlate with the level of TH 
phosphorylation at Ser31 (Salvatore, 2014). Thus, we quantified pTH-Ser31 in 
nRictor KO mice relative to CTR animals. Indeed, phosphorylation of TH at Ser31 
is reduced in nRictor KO mice with respect to CTR animals (Fig. 7C; t(12)=6.0, 
p<0.001, unpaired t-test).These data reveal a strong association between 
mTORC2 signaling, TH phosphorylation and the ability of AMPH to cause DA 
efflux. In line with the down regulation of pTH-Ser31, we found a reduction in DA 
and its metabolites in the dorsal striatum tissue of nRictor KO animals, as well as 
a consistent increase in tyrosine, the DA precursor (Fig. 7D; DA: t(21)=2.6; 
tyrosine: t(8)=2.9; DOPAC: t(22)=3.6; HVA: t(21)=4.7; *p<0.05; **p<0.01, 
***p<0.001, unpaired t-test). 
Elevated striatal expression of D2R and pERK1/2 in nRictor KO mice supports 
exaggerated AMPH-induced locomotion: Basal hyperlocomotion, elevated 
stereotypic counts, and the ability of AMPH to induce exaggerated hyperactivity, 
are behaviors that rely, at least in part, on increased DA tone in the dorsal 
striatum (Bardo et al., 1990; Rebec, 2006). However, nRictor KO animals exhibit 
reduced AMPH-induced DA release (Figure 3). This is consistent with lowered 
DA tissue content and attenuated phosphorylation of TH at Ser31. Thus, it is 
possible that altered expression and/or function of DA receptors (e.g., D1R and 
D2R) are involved. In support of this hypothesis are data demonstrating that mice 
with elevated striatal D2R expression display increased locomotion in a novel 
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environment (Kramer et al., 2011). Further, toxin ablation and functional 
disruption of D2R-expressing striatopallidal medium spiny neurons (MSN) inhibits 
locomotor activity (Durieux et al., 2009; Bateup et al., 2010). Consistently, we 
found total protein levels of D2R in the dorsal striatum of nRictor KO mice to be 
significantly elevated relative to CTR animals, (Fig. 8A; t(26)=3.3, p<0.01, 
unpaired t-test). Surface expression of D2R determined by slice-surface 
biotinylation was also significantly increased (CTR 100±12.7; nRictor KO 
245±49.0; t(8)=3.8, p<0.01, paired t-test). To corroborate these findings, we 
isolated plasma membranes from the dorsal striatum tissue, and observed 
elevated [3H]-nemonapride (a potent D2R antagonist) binding in the nRictor KO 
mice, further evidence of increased D2R (Fig. 8B; t(17)=1.9, p<0.05, unpaired t-
test). Importantly, the levels of D1R in the nRictor KO mice were not significantly 
different from those of CTR (Fig. 8C; t(23)=1.19, p>0.05, unpaired t-test). 
 Activation of D2R results in enhanced phosphorylation of extracellular signal-
related kinase (ERK1/2) (Luo et al., 1998; Cai et al., 2000; Wang et al., 2005; 
Bolan et al., 2007). The relationship between D2R signaling, ERK1/2 
phosphorylation, and locomotion has been defined by Cai and collaborators, who 
demonstrated that activation of ERK1/2 in DA-deficient dorsal striatum is required 
for D2R signaling to drive locomotor hyperactivity (Cai et al., 2000). Here, we 
observe that the increase in D2R expression in nRictor KO mice leads to a 
marked basal increase in striatal pERK1/2 (Fig. 8D; t(12)=3.0, p<0.01, unpaired 
t-test). 
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Figure 8. Elevated expression of D2R and not D1R increases pERK1/2 in 
the nRictor KO mice. A) Representative immunoblots (top) and optical density 
quantitation (bottom) of D2R expression in the dorsal striatum of nRictor KO and 
CTR animals. Actin was probed as a loading control. Data are expressed as 
percent of CTR  B) [3H]nemonapride binding to striatal plasma membranes of 
CTR and nRictor KO mice: nonspecific binding (in the presence of 10µM 
sulpiride) was subtracted from the specific binding which was counted in 
duplicates in DPM and averaged within a sample. Data normalized to CTR levels  
C) Representative immunoblots (top) from striatal homogenates obtained from 
nRictor and CTR mice probed with D1R antibody, and quantitation of the 
respective optical densities (bottom). Data are shown as a percent of control. 
Actin immunoblots served as a loading control  D) Representative immunoblot 
and quantification of pERK1/2 (shown as a percent of control) and total ERK in 
the dorsal striatum of CTR and nRictor KO. Actin is the loading control. 
 
In order to determine the role of D2R in the hyperlocomotion observed in nRictor 
KO mice, we first tested the effect of haloperidol, a typical antipsychotic and D2R 
antagonist, on ERK1/2 phosphorylation in the dorsal striatum. Haloperidol was 
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administered (0.8 mg/kg i.p., a dose of therapeutic relevance) to efficiently block 
the elevated D2R of nRictor KO mice (Clapcote et al., 2007; Lipina et al., 2010). 
One hour after injection, mice were euthanized and dorsal striatal homogenates 
probed for pERK1/2. In nRictor KO mice, haloperidol reduced pERK1/2 to CTR 
levels (Fig. 9A; t(16)=1.7, p<0.05, unpaired t-test), indicating that the enhanced 
D2R signaling causes increased ERK1/2 phosphorylation in the KO animals. 
D2R are involved in the symptomology of patients with neuropsychiatric 
disorders, and human imaging studies show elevated efficacy of DA to stimulate 
D2R in both drug naïve and treated schizophrenia patients (Abi-Dargham et al., 
2000). Next, we determined whether blockade of D2R with haloperidol 
(administered as above) alters levels of pTH-Ser31 in nRictor KO animals.  In 
nRictor KO mice, haloperidol significantly increased levels of pTH-Ser31 with 
respect to saline injected animals (Fig. 9B; t(16)=3.9, p<0.01, unpaired t-
test).This data indicates that enhanced D2R signaling contributes, a least in part, 
to the decreased pTH-Ser31 in the KO animals. To further define the role of D2R 
in the phenotypes of the nRictor KO mice, we tested whether haloperidol would 
block the exaggerated response to AMPH in nRictor KO mice. Co-administration 
of haloperidol with AMPH reversed the exaggerated AMPH-induced hyperactivity 
of nRictor KO mice, reducing their locomotor activity to the level of CTR mice 
(Fig. 9C: locomotor activity represented as area under the curve from the time of 
injection to 60 min, AMPH treatment: t(9)=2.4, *p<0.05, unpaired t-test; AMPH + 
Haloperidol (AMPH Haldol) treatment: t(9)=1.2, p>0.5, unpaired t-test). 
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Figure 9. Treatment with haloperidol supports the role of D2R in 
exaggerated AMPH-induced hyperactivity in nRictor KO mice, while viral 
intervention reveals that Akt signaling specifically in the dorsal striatum 
supports this phenotype. A) Acute administration of haloperidol reduced 
expression of pERK1/2 in the dorsal striatum of nRictor mice. (top) 
Representative immunoblots for pERK1/2 from striatal tissue of CTR and nRictor 
mice injected either vehicle or haloperidol (Haldol). (bottom) Data were 
normalized to saline injected CTR. B) Acute administration of haloperidol (i.p., 
0.8mg/kg) decreased expression of pTH-Ser31 in the dorsal striatum of nRictor 
mice. (top) Representative immunoblots for pTH-Ser31 and total TH obtained 
from striatal tissue of CTR and nRictor mice injected either vehicle or haloperidol 
(Haldol). (bottom) Data were normalized to the correspondent total TH and 
expressed as a percent of saline injected CTR.  C) CTR and nRictor KO mice 
were habituated to saline injections and open field chambers for six days. On day 
seven drugs were administered and horizontal locomotor activity recorded in 5-
min intervals. Data are represented as area under the curve from time of injection 
to 60 min. D) Viral downregulation of striatal Rictor results in decreased pAkt-
473: AAV-Cre-GFP and AAV-eGFP viral vectors were injected into the dorsal 
striatum of floxed animals. Shown are representative immunoblots of AAV-Cre 
injected animals vs. AAV-eGFP CTRs. Inset: representative images (4X) 
demonstrating GFP in the targeted brain region: white light on the left; FITC filter 
on the right. E) AMPH (i.p. 2mg/kg) induced locomotion measured following the 
same handling/habituation protocol as was used for the genetic KO. Data are 
represented as area under the curve from the time of injection to 60 min.  
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Reduced mTORC2 signaling in the dorsal striatum supports exaggerated AMPH-
induced hyperactivity: Recombinant adeno-associated viral vectors (rAAV) are 
widely used for temporally and spatially controlled gene delivery. Out of many 
naturally available serotypes, rAAV-5 was shown to be the most efficient for 
genetic transduction in the dorsal striatum of mice (Aschauer et al., 2013) and 
non-human primates (Markakis et al., 2010). In order to strengthen our 
hypothesis that AMPH-induced hypersensitivity of nRictor KO animals stems, at 
least in part, from impaired mTORC2 signaling specifically in the dorsal striatum, 
we selectively deleted Rictor by injecting rAAV-Cre into the dorsal striatum of 
floxed Rictor mice. For biochemical assessment, floxed Rictor animals were 
injected unilaterally with rAAV-Cre, while the other hemisphere was injected with 
rAAV-eGFP as a control. Light and fluorescence microscopy confirmed 
localization of injections to dorsal striatum (Fig. 9D top). Dorsal striata injected 
with rAAV-Cre showed a reduction in pAkt-473 compared to rAAV-eGFP injected 
striata (Fig. 9D bottom). Four weeks after bilateral rAAV-Cre injection, animals 
exhibited exaggerated AMPH-induced hyperlocomotion relative to rAAV-eGFP 
animals (Fig. 9E: locomotor activity represented as area under the curve from the 
time of injection to 60 min, t(12)=2.2, p<0.05, unpaired t-test). 
 
Discussion 
 
  The mTORC2 complex is responsible for phosphorylation of AGC kinases 
to promote their maturation, stability and allosteric activation (Oh and Jacinto, 
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2011). These kinases include Akt, serum/glucocorticoid regulated kinase 1 
(SGK1) and protein kinase Cα (PKCα). Clinical evidence supports a role for Akt 
in DA-dependent mental illness (Emamian et al., 2004; Lu and Dwyer, 2005; 
Krishnan et al., 2008). Nonetheless, the molecular mechanisms linking altered 
mTORC2/Akt signaling to impaired DA neurotransmission and corresponding 
behaviors have been elusive. Here, we demonstrate how genetic deletion of 
Rictor protein and the parallel reduction of pAkt-473 in the brain results in altered 
striatal DA tone.  
 Our laboratory has extensively studied how Akt signaling influences DA tone 
in the brain (Williams et al., 2007; Speed et al., 2010; Speed et al., 2011). These  
published data reveal that Akt function supports DAT surface expression .  Here 
we expand upon these findings, demonstrating that genetic deletion of the 
protein Rictor causes a reduction in Akt Ser473 phosphorylation and an increase 
in DAT expression.  These data are consistent with a differential role of Akt 
Ser473 phosphorylation and Akt function in DA homeostasis.  However, in the 
current study, we cannot rule out the possibility that other AGC kinases regulated 
by mTORC2 participate in this process. These data warrant further mechanistic 
investigation to understand the differential effects that perturbations of the 
mTORC2 pathway might have on central DA neurotransmission. In this context, it 
is important to point out seminal work by Mazei et al. (Mazei-Robison et al., 
2011).    
 Here we show that genetic disruption of mTOR/Rictor signaling in the brain 
in nRictor KO mice behaviorally manifests in novelty-induced hyperactivity and 
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AMPH hypersensitivity, two phenotypes that have been associated in animal 
models with schizophrenia (Gainetdinov et al., 2001). These behaviors were 
mechanistically supported by both pre- and post-synaptic changes in the DA 
system. These include diminished DA bioavailability and elevation in D2R and its 
downstream signaling. Further, we demonstrate that mTORC2 signaling 
specifically in the dorsal striatum regulates AMPH-induced locomotion. 
 Striatum is a basal ganglia nucleus critically involved in integrating motor 
control, reward, and motivation. It is also implicated in brain disorders such as 
Parkinson’s and Huntington's disease, drug addiction, and schizophrenia 
(Nestler, 2005; Kellendonk et al., 2006; Kreitzer and Malenka, 2008; Simpson et 
al., 2010; Durieux et al., 2012). Studies in animal models link stereotypy to 
aberrant DA signaling in the dorsal striatum (Kelly et al., 1975; Andrews et al., 
1982; Carr and White, 1984; Porrino et al., 1984; Sharp et al., 1987). Our results 
demonstrate that global brain impairment of mTORC2 signaling results in 
hyperactivity, increased stereotypy, and exaggerated response to AMPH. A 
limitation to the genetic approach undertaken here is that nRictor KO mice have 
reduced brain size (Siuta et al., 2010). Therefore, we cannot exclude the 
possibility that the observed phenotype was influenced by developmental 
impairment. However, virally mediated deletion of Rictor specifically in the dorsal 
striatum of adult mice significantly increased the ability of AMPH to stimulate 
locomotion, recapitulating, at least in part, nRictor KO mouse behavior. Overall, 
our data strongly support a primary role for mTORC2 signaling in modulating 
striatal DA neurotransmission. 
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  AMPH-induced changes in behavior are caused by elevated intra-synaptic 
DA promoted by non-vesicular DAT-mediated DA release (Fischer and Cho, 
1979; Sulzer et al., 2005; Rebec, 2006; Hamilton et al., 2014). Surprisingly, we 
found a decrease in DA bioavailability in response to AMPH in the dorsal striatum 
of nRictor KO mice. This finding is further supported by the observed reduction of 
tissue DA levels, as well as lowered pTH-Ser31. This key phosphorylation site 
correlates with TH activity in vivo, and is a reliable predictor of DA tissue content 
(Salvatore et al., 2009; Damanhuri et al., 2012; Salvatore and Pruett, 2012). All 
together these data suggest the involvement of compensatory mechanisms that 
employ DA receptors for the observed behavior. In this respect, the nRictor KO 
mouse represents a unique model of aberrant brain mTORC2 signaling causing 
a plethora of changes in central DA neurotransmission including altered D2R 
signaling.  The finding that nRictor KO mice have elevated D2R expression, with 
no change observed in D1R levels, supports this hypothesis.  
  nRictor KO mice have reduced striatal DA content in the context of elevated 
D2R. These data are in line with previous studies suggesting that striatal DA 
depletion leads to an increase in D2R, and not D1R expression (Dewar et al., 
1990; Radja et al., 1993). However, we cannot exclude the possibility that 
overexpression of D2R drives the reduction in DA content. In support of this 
mechanistic hypothesis, acute administration of haloperidol increased TH 
phosphorylation at Ser31 in nRictor KO mice. We also hypothesize that 
increased D2R expression drives the nRictor KO behavioral phenotype. 
Consistent with this hypothesis, the AMPH locomotor hypersensitivity of these 
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mice was blocked by the D2R inhibitor, haloperidol. The involvement of D2R in 
the regulation of locomotion is further supported by D2R-eGFP mice, which 
overexpress D2R in the medium spiny neurons and exhibit higher basal activity 
(Kramer et al., 2011). Therefore, elevated D2R in this model appears to drive 
both reduced DA synthesis and hypersensitivity to AMPH.  
 In nRictor KO animals with impaired mTORC2 signaling phosphorylation of 
ERK1/2 is markedly elevated, a known downstream target of D2R activation (Luo 
et al., 1998; Cai et al., 2000; Wang et al., 2005; Bolan et al., 2007). Therefore, 
the observed increase in D2R expression in nRictor KO mice likely accounts for 
the increase striatal ERK1/2 phosphorylation. This possibility is strengthened by 
the finding that haloperidol treatment lowered ERK1/2 phosphorylation in nRictor 
KO mice. Prior studies have shown that in DA-depleted striatum, pERK1/2 was 
increased in response to D2R, but not D1R stimulation, which led to a 
characteristic rotating phenotype that could be blocked by the inhibition of 
MAPK/ERK pathway (Cai et al., 2000). In addition, a recent study revealed that 
disruption of upstream activators of the Akt signaling pathway in D2R expressing 
striatopallidal MSNs, results in spontaneous and drug-induced hyperlocomotion 
along with an increase in ERK1/2 phosphorylation (Besusso et al., 2013). Taken 
together, our data suggest a “cross-talk” between mTORC2 function and D2R-
ERK1/2 signaling that drives specific DA-dependent dorsal striatum-associated 
behaviors. Indeed, the significant increase in striatal pERK1/2 was restored to 
control levels with an acute treatment of haloperidol, a typical antipsychotic and 
D2R antagonist. Furthermore, our behavior experiments demonstrate that 
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haloperidol blocks the exaggerated AMPH-induced hyperlocomotion in mice with 
reduced brain mTORC2 signaling.   
  In this study we functionally isolate the dorsal striatum as a brain region 
where mTORC2 signaling regulates DA-dependent behaviors by altering D2R 
signaling. D2R are clearly involved in schizophrenia, supported by the fact that 
typical antipsychotics that target D2R alleviate schizophrenic symptoms in 
humans (Chouinard et al., 1993; Min et al., 1993; Odou et al., 1996; Kasper et 
al., 1997). Furthermore, D2R antagonists attenuate schizophrenia-like 
phenotypes associated with striatal DA dysfunction in animal models (Cazorla et 
al., 2014). Here, we show that aberrant mTORC2 signaling in the dorsal striatum 
is sufficient to alter fundamental DA-dependent behaviors in mice. Furthermore, 
we demonstrate that reduction of mTORC2 function influences DA levels in the 
dorsal striatum, and causes abnormal D2R signaling that leads to aberrant 
phosphorylation of ERK1/2, ultimately supporting the observed basal and AMPH-
induced hyperactivity in the KO animals.  
 Translational relevance:  Our prior findings reveal that nRictor KO mice have 
altered cortical DA neurotransmission associated with impaired pre-pulse 
inhibition (Siuta et al., 2010). Besides cortical circuits, dysregulated striatal DA 
neurotransmission is also thought to be fundamental to the etiology of 
schizophrenia (Davis et al., 1991a; Abi-Dargham et al., 2000; Howes and Kapur, 
2009). Pivotal evidence supporting the DA hypothesis of schizophrenia stemmed 
from studies investigating psychotogenic effects of psychostimulants (Lieberman 
et al., 1987). Psychostimulants, including AMPH, disrupt striatal DA homeostasis 
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(Rebec, 2006). Importantly, they were shown to cause paranoia and psychosis in 
healthy individuals, and further exacerbate psychoses in schizophrenic patients 
(Lieberman et al., 1987). Imaging studies implicate the dorsal striatum in AMPH 
responses in both healthy humans and patients with schizophrenia (Weinberger 
and Laruelle, 2002). This study enhances our understanding of how metabolic 
signaling via mTORC2 can influence DA neurotransmission in brain and reveals 
that mTORC2 is a pivotal regulator of striatal DA neurotransmission and AMPH 
action. Our data also support dysfunction of mTORC2 signaling as a possible 
mechanism underlying in the etiology of schizophrenia.      
 
Materials and Methods 
 
All procedures were performed according to Vanderbilt University Institutional 
Animal Care and Use Committee approved procedures. 
 
Generation of mice 
Mice were engineered as described previously (Siuta et al., 2010). Briefly, mice 
with floxed Rictor alleles were crossed to Nestin-Cre transgenic animals to 
produce neuron specific Rictor knockout mice (rictor f/f Nes+/+ or +/-; nRictor 
KO). Control mice (CTR) were littermates that lacked Cre recombinase. All mice 
were backcrossed to C57Bl6 background for at least 10 generations. To 
genotype the animals, DNA from tail clippings was analyzed by PCR with primers 
for the floxed, nestin, and recombined alleles as previously described (Shiota et 
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al., 2006). 
Brain slice preparation and biotinylation 
For brain slice preparation and biotinylation, all procedures were performed as 
previously described (Robertson et al., 2010). Briefly, 8-30 week old mice were 
sacrificed by rapid decapitation, and corticostriatal (300 µm) slices were prepared 
with a vibratome (Leica VT1000S) in ice cold oxygenated (95% O2 / 5% CO2) 
sucrose solution (sucrose 210 mM; NaCl 20 mM; KCl 2.5 mM; MgCl2 1 mM; 
NaH2PO4•H2O 1.2 mM). Slices were then collected in oxygenated artificial 
cerebral spinal fluid (ACSF) (NaCl 125 mM, KCl 2.5 mM, NaH2PO4•H2O 1.2 
mM, MgCl2 1 mM, CaCl2•2H2O 2 mM), washed twice with oxygenated 4°C 
ACSF, and then incubated with 4°C ACSF solution containing 1 mg/mL of EZ-
Link Sulfo-NHS-SS-Biotin (Pierce/ThermoScientific; Rockford, IL) for 45 min. 
After biotin incubation, the slices were rinsed, washed, and the reaction 
terminated with ACSF containing glycine. Dorsal striatum slices from CTR and 
nRictor KO mice were anatomically paired, dissected on ice, and frozen at −80°C 
until use. After homogenization, biotinylated (surface proteins) fraction was 
isolated with ImmunoPure immobilized streptavidin beads (Pierce). Total slice 
lysates and biotinylated fractions underwent immunodetection for dopamine (DA) 
transporter (DAT) and DA D2 receptor (D2R). 
 
Tissue harvest. Monoamine, metabolites, and amphetamine (AMPH) 
content  
Mice (8-30 weeks old) were sacrificed by rapid decapitation under volatile 
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isoflurane anesthesia, brains were removed and chilled on ice. Dorsal striatum 
was dissected out from two hemispheres to create comparable samples for both 
monoamine content and immunoblotting. After dissection, tissue was frozen on 
dry ice and stored in -80°C until use. Monoamine content was determined at the 
Vanderbilt University Neurochemistry Core via high performance liquid 
chromatography (HPLC) with amperometric detection as described previously 
(Robertson et al., 2010). To evaluate AMPH concentration in the dorsal striatum, 
procedures as above were followed in mice injected with 2 mg/kg AMPH i.p. 30 
min prior to decapitation.   
 
Immunoblotting 
Tissue was lysed in 1% Triton lysis buffer (25 mM Hepes, 150 mM NaCl, 2 mM 
sodium orthovanadate, 2 mM NaF, plus a cocktail of protease inhibitors and 
phosphatase inhibitors) and centrifuged at 17,000g for 30 min at 4°C. 
Supernatant was collected into 0.1% Triton pulldown buffer (25 mM HEPES, 150 
mM NaCl, 2 mM sodium orthovanadate, 2 mM NaF, plus a cocktail of protease 
inhibitors and phosphatase inhibitors). Protein concentration was determined 
using Bio-Rad protein concentration kit and all samples were equalized for total 
protein amount. Proteins were denatured with SDS-PAGE sample loading buffer 
at 95°C for 5 min, cooled to room temperature, and separated by 10% SDS-
PAGE. Resolved proteins were then transferred to polyvinylidene difluoride 
(PVDF) membrane and blocked in either 5% milk or 2.5% BSA in 0.1% Tween20 
Tris-buffered saline. Blots were then incubated in primary antibody rocking either 
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at room temperature for 1 hour or overnight at 4°C. The primary antibodies used 
in this study included Akt (1:1000, Cell Signaling Technology), phospho-Akt 
serine 473 (pAkt-Ser473) (1:800, Cell Signaling Technology), D2R (1:100; Santa 
Cruz Biotechnology), D1 DA receptor (1:500; Sigma-Aldrich, US), tyrosine 
hydroxylase (1:1000; Cell Signaling Technology; Danvers, MA), phospho-
tyrosine hydroxylase serine 31 (1:800; Cell Signaling Technology; Danvers, MA), 
DA transporter (1:1000; Dr. Roxanne Vaughan, University of North Dakota 
School of Medicine), ERK 1/2 (1:1000; Promega; Madison, WI), phospho-ERK 
1/2 (1:800; Promega; Madison, WI), β-actin (used as a loading control; 1:1000; 
Sigma-Aldrich; St. Louis, MO), Na-K ATPase (used as a control for biotinylation; 
1:1000; DSHB, Department of Biology, The John Hopkins University). All proteins 
were detected using HRP conjugated secondary antibodies (1:4000; Santa Cruz 
Biotechnology, Santa Cruz, CA). After chemiluminescent visualization 
(PerkinElmer, Inc., Waltham, MA) on Hyblot CL film (Denville Scientific, South 
Plainfield, NJ), protein band densities were quantified using ImageJ software 
(ImageJ, National Institutes of Health, Bethesda, MD).  
 
Ex-vivo DA uptake 
Corticostriatal slices were prepared as described above. After collection, slices 
were allowed to recover in 28°C oxygenated ACSF for one hour. The slices were 
then placed into 37°C ACSF uptake buffer for 10 min (NaCl 125 mM, KCl 2.5 
mM, NaH2PO4•H2O 1.2 mM, MgCl2 1 mM, CaCl2•2H2O 2 mM, pH 7.4) 
containing [3H]-DA (50 nM). Immediately after uptake, slices were washed in ice-
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cold ACSF three times, homogenized in 1% Triton lysis buffer (see 
Immunoblotting), and spun down at 17,000g for 30 min at 4°C. Supernatant was 
collected into 0.1% Triton pulldown buffer, and samples equalized for total 
protein concentration. Ecoscint H scintillation solution (National Diagnostics, 
Atlanta, GA) was added to samples and they were quenched overnight, after 
which radioactivity was measured. Specific uptake was defined as total uptake 
minus uptake obtained in the presence of 10 µM cocaine (non-specific uptake). 
 
Locomotor behavior 
Male mice (8–12 weeks old), were housed in temperature and humidity 
controlled rooms and kept on a 12-h light/dark cycle. Food and water were 
available ad libitum. Experiments were conducted in accordance with the NIH 
guidelines for the care and use of animals and were approved by the Vanderbilt 
University Institutional Animal Care and Use Committee. Initial handling lasted 5 
days, with daily i.p. saline injections. On day 6 mice were tested for open field 
locomotor activity. Four hour long sessions were performed using automated 
experimental chambers (27.9×27.9 cm; MED-OFA-510; MED Associates, 
Georgia, VT) under constant illumination in a sound-attenuated room. During 
days 7-12 mice were habituated to the chambers and saline injections: four hour 
sessions with two saline injections daily (at times -120 min and 0 min). On day 
13, mice were injected with saline at time -120 min and allowed to explore the 
chambers for two hours to settle to comparable baseline. At time 0 min, drugs or 
vehicle were administered i.p. (AMPH 2mg/kg; haloperidol 0.8mg/kg in DMSO) 
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and locomotion recorded for the next two hours. Analysis of open field activity, as 
well as stereotypic counts was performed using Activity Monitor (MED 
Associates).  
 
In-vivo microdialysis 
Mice under anesthesia with isoflurane were placed in a stereotaxic frame (Kopf 
Instruments) with a mouse adapter. A guide cannula (CMA7 microdialysis, USA) 
was placed above the dorsal striatum (+1.4 AP, ±1.4 ML from Bregma and −0.9 
DV from dura for CTR mice, and +1.0 AP, ±1.4 ML from Bregma and −0.3 DV 
from dura for nRictor KO mice) and secured to the skull with epoxy adhesive 
(Plastics One). Animals were allowed 24 hours to recover from the surgery. One 
day before the experiment, animals were placed in individual dialysis chambers 
and the microdialysis probe (CMA7 microdialysis, USA) with the active length of 
2mm was inserted into the guide cannula. One end of a tether (Plastics One) was 
attached to a harness and the other end attached to a swivel (Instech) mounted 
on a counterbalanced arm above the dialysis chamber. The probe was perfused 
overnight at a flow rate of 0.5 µL/min with artificial cerebral spinal fluid containing 
149 mM NaCl, 2.8 mM KCl, 1.2 mM CaCl2, 1.2 mM MgCl2, 5.4 mM d-glucose, 
pH 7.2. On the day of the experiment the flow rate was changed to 1.0 µL/min 
and after equilibration, dialysis fractions (20 min each) were collected to establish 
baseline concentrations of neurotransmitter efflux. Dialysate samples were 
stored at −80°C and analyzed by HPLC-EC for DA levels. Probe placement was 
verified after collection of slices. 
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Ex vivo high speed chronoamperometry 
Corticostriatal slices were prepared and allowed to recover as specified above for 
DA uptake. DA concentration was measured by chronoamperometry in the dorsal 
striatum as previously described (Hoffman and Gerhardt, 1999; Gerhardt and 
Hoffman, 2001). Briefly, carbon fiber electrodes (100 μm length × 30 μm O.D.) 
coated with nafion for dopamine selectivity were lowered into the dorsolateral 
portion of the striatum so that the tip of the recording electrode was positioned at 
a depth of 75-100 μm. The voltage was stepped from 0 mV to 550 mV for 100 ms 
and then back to 0 mV and the charging current of the carbon fiber electrode was 
allowed to decay for 20 ms before the signals were integrated. Data were 
collected at a frequency of 1 Hz with an Axopatch 200B amplifier. The integrated 
charge was converted to dopamine concentration based on in vitro calibration 
with dopamine.  
 
Radioactive nemonapride binding  
Dorsal striatum tissue was harvested as described, and stored at -80°C until 
processed. To quantitatively assess D2R expression, plasma membranes were 
obtained by tissue homogenization in 10 volumes of ice-cold 50mM Tris-HCl 
buffer (containing also 1mM EDTA, 5mM MgCl2, 1.5mM CaCl2, 120mM NaCl, 
5mM KCl, pH 7.4), and then centrifuged at 40,000 × g for 30 min. The pellet was 
re-suspended in ice-cold 50mM Tris-HCl buffer (containing 1mM EDTA, 5mM 
MgCl2, 1.5mM CaCl2, 120mM NaCl, 5mM KCl, 12µM pargyline, 0.1% ascorbic 
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acid, pH 7.4), after which protein content was determined by Bradford method. 
Samples were diluted to the same final protein concentration. 
D2R binding assay was performed on ice, using 1.5nM [3H]nemonapride to 
determine Vmax. Nonspecific binding was determined using 10µM sulpiride. For 
the ligand-binding assays, the membrane preparations were incubated on a 
shaker (to prevent precipitation of the membranes) for 60 min in a final volume of 
200µL. The reaction was stopped by rapid filtration through Whatman GF/A glass 
fiber filters. Filters were washed twice with 5 mL of ice-cold 50mM Tris-HCl 
buffer, and, after an overnight incubation, assayed for radioactivity on a liquid 
scintillation counter. Ligand binding was determined by average of duplicates 
with subtraction of non-specific binding, which was observed in the presence of 
10µM sulpiride (30-35%). 
 
Stereotactic surgeries and viral injections  
Mice were anesthetized with isoflurane and placed in a stereotaxic frame (Kopf 
Instruments) with subsequent injection into two striatal locations. The tip of a 
5.0μl Hamilton microsyringe needle (30-gauge) was inserted to stereotaxic 
coordinates relative to bregma: anterior-posterior (AP) +0.75cm; medial-lateral 
(ML) +/-1.50cm; and dorsal-ventral (DV) −3.57cm, and second DV coordinate, -
3.00cm. Viral vector suspension in a volume of 1.5μl per hemisphere (0.750μl 
into each DV site) was injected at 0.15μl/min. After microinjection, the needle 
was left for 3 min before withdrawal to reduce the efflux of injectate along the 
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injection tract. Mice were excluded from injection failures. For the biochemical 
assessment, the mice were injected with rAAV-Cre into the right hemisphere, and 
with rAAV-eGFP into the left as control. Animals were sacrificed 3 weeks after 
microinjection, and analyses of the dorsal striatum tissue was performed as 
described above. For the behavioral experiments, mice were injected bilaterally 
with either rAAV-Cre or rAAV-eGFP, and locomotor behavior and AMPH-induced 
hyperactivity were assessed as described above.  
 
Statistical analysis 
All data are expressed as the mean ± SEM. Mean differences between groups 
were determined using Student’s t test or two-way ANOVAs followed by post hoc 
testing when the main effect or interaction was significant at p < 0.05. Statistical 
analyses were conducted using GraphPad Prism. The number of animals and 
specific statistical analyses used in each experiment are indicated in the text.	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CHAPTER III 
 
IMPAIRED mTORC2 SIGNALING IN CATECHOLAMINERGIC NEURONS 
EXAGGERATES HIGH FAT DIET-INDUCED HYPERPHAGIA* 	  
Abstract 
	  
Objective: Food intake is highly regulated by central homeostatic and hedonic 
mechanisms in response to peripheral and environmental cues. Neutral energy 
balance stems from proper integration of homeostatic signals with those 
“sensing” the rewarding properties of food. Impairments in brain insulin signaling 
causes dysregulation of feeding behaviors and, as a consequence, hyperphagia. 
Here, we sought to determine how the mammalian target of rapamycin complex 
2 (mTORC2), a complex involved in insulin signaling, influences high fat feeding.  
	  
Methods: Rictor is a subunit of mTORC2, and its genetic deletion impairs 
mTORC2 activity. We used Cre-LoxP technology to delete Rictor in tyrosine 
hydroxylase (TH) expressing neurons (TH Rictor KO). We assessed food intake, 
body weight, body composition and DA dependent behaviors.  
 
* The work presented in this chapter is in press as Olga I. Dadalko, Kevin D. Niswender, Aurelio Galli 
(Heliyon) 2015. 
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Results: TH Rictor KO mice display a high-fat diet specific hyperphagia, yet, 
when on low-fat diet, their food intake is indistinguishable from controls.  
Consistently, TH Rictor KO become obese only while consuming high-fat diet.  
This is paralleled by reduced brain DA content, and disruption of DA dependent 
behaviors including increased novelty-induced hyperactivity and exaggerated 
response to the psychostimulant amphetamine (AMPH).  
 
Conclusions: Our data support a model in which mTORC2 signaling within 
catecholaminergic neurons constrains consumption of a high-fat diet, while 
disruption causes high-fat diet-specific exaggerated hyperphagia. In parallel, 
impaired mTORC2 signaling leads to aberrant striatal DA neurotransmission, 
which has been associated with obesity in human and animal models, as well as 
with escalating substance abuse. These data suggest that defects localized to 
the catecholaminergic pathways are capable of overriding homeostatic circuits, 
leading to obesity, metabolic impairment, and aberrant DA-dependent behaviors. 
 
Introduction 
 
A range of factors contributes to obesity, including nutritional trends, 
availability of highly palatable foods, changes to the built environment, economic 
stresses, and others (Mokdad et al., 2003). Feeding is a centrally controlled 
complex biological behavior fine-tuned by both homeostatic metabolic drive 
(hunger or satiety) and hedonic motivational drive (reward and salience). 
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Therefore, identifying the neurobiological circuits in which deficits lead to the 
development of both positive energy balance (i.e. “homeostatic” or “metabolic” 
obesity) and/or exaggerated responses to palatable food (i.e. “hedonic” obesity) 
is essential for defining mechanisms involved in the central regulation of food 
intake.  
Akt is a key insulin dependent kinase that influences both peripheral 
endocrine responses and higher brain functions such as learning and memory, 
reward, and salience (Bae et al., 2003; Beaulieu et al., 2004; Russo et al., 2007; 
Kumar et al., 2008; Miller et al., 2014; Wong et al., 2015). Akt is activated by 
phosphorylation of two key residues, Thr308 and Ser473. Mammalian target of 
rapamycin (mTOR) complex 2 (mTORC2) is a multiprotein complex responsible 
for phosphorylation of Akt at Ser473 (pAkt-473). Within hypothalamic neurons, 
mTORC2 activity is implicated in mechanisms that control homeostatic 
neuroendocrine responses (Kocalis et al., 2014). In the catecholaminergic 
system, mTORC2 function regulates monoamine turnover, DA 
neurotransmission, as well as psychostimulant action (Siuta et al., 2010; Speed 
et al., 2011; Dadalko et al., 2015). These processes are implicated in reward and 
salience (Daws et al., 2011). This concept is also supported by data 
demonstrating that impairment in mTORC2 signaling leads to escalating 
morphine self-administration (Mazei-Robison et al., 2011).  
The mTORC2 complex consists of Rictor, mSIN1, mLST8, and mTOR.  
Recent studies show that conditional deletion of Rictor in hypothalamic centers 
leads to hyperphagia, impaired peripheral glucose homeostasis, and obesity 
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(Kocalis et al., 2014). In order to determine whether Rictor function specifically 
within catecholaminergic neurons plays a role in feeding behaviors and 
metabolism, we crossed Rictor-Flox mice with mice expressing Cre recombinase 
under control of the tyrosine hydroxylase (TH) promoter (TH Rictor KO). We 
show that disruption of mTORC2 signaling within catecholaminergic circuits 
supports exaggerated hyperphagia in response to palatable high-fat diets.  
 
Results 
 
Rictor deletion within catecholaminergic circuits results in increased lean 
mass. We first assessed body weight and composition, as well as feeding in 
animals consuming a low fat diet for 8 weeks (LF, 10% fat). TH Rictor KO mice 
weigh more than control (CTR) mice (Fig. 10A; CTR mice were littermates of TH 
Rictor KO mice that lacked Cre recombinase).  The increase in body weight is 
due to elevated lean mass as determined by NMR (Fig. 10A). DA neurons in the 
hypothalamus have been shown to regulate plasma growth hormone (GH) 
concentration (Bosse et al., 1997). The increase in lean mass, therefore, could 
stem from elevated GH levels. There were no differences in GH between 
genotypes (data not shown). Importantly, cumulative food intake was not different 
for TH Rictor KO mice relative to CTR animals (Fig. 10B) while on the LF diet. 
Feed efficiency, the change in total body weight, fat, or lean mass divided by the 
cumulative calories consumed over a period of time was not different (Fig. 10C).  
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These data strongly suggest that TH Rictor KO mice with disrupted mTORC2 
signaling within catecholaminergic neurons have intact homeostatic energy 
regulation. However, since catecholamines are implicated in salience and 
reward, we next determined the role of mTORC2 signaling on the intake of a high 
fat (HF, 60% fat), palatable diet.  
 
 
Figure 10. Energy balance and body composition of TH Rictor KO mice on 
low-fat diet (LF). (A) Body composition of TH Rictor KO and CTR mice; n=8 per 
genotype (B) Cumulative food intake (LF diet) was measured over the course of 
eight weeks and was found to be indistinguishable from the LF food intake of 
CTR animals; n=6-7 per genotype. (C) Feed efficiency over the corresponding 
eight week period was calculated as change in total body weight, fat, or lean 
mass in grams divided by total kcal consumed. Values represent mean±SEM; *** 
p<0.001.  
 
Conditional deletion of Rictor in catecholaminergic neurons results in 
escalating hyperphagia on high fat (HF) diet. The mesolimbic system is an 
essential component of the circuitry that evaluates saliency of natural rewards, 
including food (Castro et al., 2015; Cone et al., 2015; McCutcheon, 2015; Perello 
and Dickson, 2015). Catecholaminergic neurons are an essential component of 
this system. Given their role in food reward, we hypothesized that mTORC2 
signaling in TH expressing neurons might play a pivotal role in regulating food 
consumption in animals exposed to palatable high fat diet (HF, 60% fat).  Unlike 
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on LF diet, TH Rictor KO mice consume significantly more calories than CTR 
animals on HF diet (Fig. 11A, inset).  When excess HF diet intake is visualized 
 
 
 
Figure 11. Energy balance of TH Rictor KO mice on high-fat diet (HF). (A) 
Genotype-specific difference in cumulative consumption of HF food relative to LF 
food consumption (average low-fat food intake was subtracted from high-fat food 
intake in kcal); n=7-9 per treatment per genotype. Inset: Cumulative food intake 
(high-fat diet) was measured over the course of eight weeks. In both graphs, 
high-fat food-induced escalating hyperphagia is shown for TH Rictor KO mice 
compared to CTR animals; n=6-7 per genotype. (B) Body composition over the 
corresponding eight week period was measured and graphed to compare with 
CTR mice; n=8 per genotype. (C) Feed efficiency over the corresponding eight 
week period was calculated as change in total body weight, fat, or lean mass in 
grams divided by total kcal consumed); n=4-5 per genotype. Values represent 
mean±SEM; *** p<0.001, ** p<0.01, * p<0.05. 
 
cumulatively by subtracting average LF diet consumption from daily HF diet 
consumption, continuously escalating HF diet consumption is observed only in 
TH Rictor KO mice (Fig. 11A). This was calculated by subtracting the average 
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caloric consumption on a low fat diet from the caloric consumption on the high fat 
diet of the correspondent genotype each day. Thus, CTR animals modulate their 
high-fat food intake, while TH Rictor animals continuously increase consumption 
of the high-fat diet over time (Fig. 11A). Concomitantly, TH Rictor KO mice show 
a rapid increase in body weight and lean mass after only six days on a high fat 
diet (Fig. 11B) without changes in feed efficiency (Fig. 11C). 
Conditional deletion of Rictor in TH expressing neurons results in impaired 
DA neurotransmission and aberrant DA-dependent behaviors. The 
catecholaminergic system modulates motivated behaviors such as feeding, 
drinking, and locomotion as well as reward. TH Rictor KO mice exhibit normal 
food intake when exposed to a LF diet. However, they display exaggerated 
hyperphagia to a HF diet. This hyperphagia could stem from disrupted DA 
neurotransmission in midbrain. To explore this possibility, we first analyzed DA 
tissue content in the ventral striatum. TH Rictor KO mice have reduced DA tissue 
content in the Nucleus Accumbens (NAc) relative to CTR animals (Fig. 12A), 
suggesting impaired mesolimbic DA tone in the conditional KO mice. Importantly, 
DA metabolites DOPAC, 3-MT, and HVA were not significantly changed in the 
TH Rictor KO mice (data not shown), suggesting faster DA metabolism. This 
hypothesis awaits further exploration.  
 
	   80	  
  
Figure 12. Aberrant NAc DA tone and disrupted DA-dependent behaviors in 
TH Rictor KO mice. (A) DA tissue content as measured by HPLC in NAc 
homogenates; n=6-8 per genotype. (B) Novelty-induced locomotion: horizontal 
movement measured in open field chambers in 5-min intervals; n=8 per 
genotype. Data are represented as area under the curve (AUC) for the first 30 
minutes in the chamber. (C) AMPH-induced locomotion; n=7-8 per treatment per 
genotype. CTR and TH Rictor KO mice were habituated to saline injections and 
open field chambers for six days. On day seven AMPH (2mg/kg) was 
administered i.p. and horizontal locomotor activity recorded in 5-min intervals. 
Data are represented as area under the curve (AUC) from time of injection to 30 
minutes. Values represent mean±SEM; ** p<0.01, * p<0.05. 
 
Analysis of locomotor activity is an efficient method to evaluate the 
integrity of the DA neurotransmission in rodents. Novelty-induced hyperactivity is 
modulated by the mesolimbic DA pathway (Bardo et al., 1990). TH Rictor KO 
mice display exaggerated hyperlocomotion in a novel environment relative to 
CTR animals (Fig. 12B). Importantly, rodents that are prone to elevated novelty-
induced hyperactivity, also exhibit heightened sensitivity to psychostimulants, 
such as amphetamine (AMPH) (Siuta et al., 2010; Kramer et al., 2011; Dadalko 
et al., 2015). Therefore, we challenged habituated (see methods) TH Rictor KO 
mice with a single dose of AMPH. TH Rictor KO animals show increased AMPH-
induced hyperactivity compared to their wild type counterparts (Fig. 12C). These 
data support the notion that genetic deletion of Rictor in the TH expressing cells 
results in altered mesolimbic DA tone associated with exaggerated high fat 
hyperphagia and AMPH-induced hyperlocomotion.  
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Discussion 
	  
Regulation of energy balance is intricately regulated by the central 
nervous system. Food intake is controlled by both homeostatic and hedonic 
circuits, which rely not only on objective physiological cues supported by 
peripheral systems, but also on subjective experiences such as memory, 
motivation, and pleasure, all supported by environmental cues (Porte et al., 2002; 
Berthoud, 2006; Daws et al., 2011; Castro et al., 2015; Perello and Dickson, 
2015). One of the key regulators of energy balance, the adiposity negative 
feedback hormone insulin, signals via mTORC2/Akt pathway in the brain, and 
modulates both homeostatic and hedonic neural circuits (Daws et al., 2011; 
Niswender et al., 2011; Kocalis et al., 2014). Proper integration of homeostatic 
signals with those “sensing” the saliency of food is necessary for appropriate 
energy balance regulation. Aberrant brain insulin signaling causes abnormal 
feeding behaviors, including hyperphagia (Speed et al., 2011) and has been 
shown to regulate catecholaminergic neurotransmission through Akt (Robertson 
et al., 2010; Siuta et al., 2010).  
Dopamine is essential in modulation of many vital behaviors including 
movement, cognition, motivation, and salience. Motivation to obtain natural 
rewards such as food is vital for the organismal survival, and was shown to 
depend on central DA neurotransmission. Indeed, motivation for seeking food as 
well as the reward and satiety we feel when we eat have been extensively 
studied in humans using imaging techniques (Volkow et al., 2003; Volkow and 
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Wise, 2005). Mere consumption of food is a motivated behavior that is controlled 
by the DA signaling (Palmiter, 2007).  
Our laboratory and others have previously shown in vitro data that 
aberrant Akt signaling, and its upstream regulators such as insulin, PI3K, and 
IRS-2 are capable of disrupting central DA neurotransmission by altering 
expression and/or function of the DA homeostasis molecular players (Carvelli et 
al., 2002; Garcia et al., 2005; Wei et al., 2007; Lute et al., 2008). In addition, our 
in vivo studies demonstrated that aberrant peripheral insulin signaling caused by 
either high-fat diet or pharmacological interventions leads to altered central DA 
signaling (Williams et al., 2007; Speed et al., 2011).  Therefore, in this study we 
sought to look if the disrupted mTORC2/rictor/Akt signaling in the TH expressing 
neurons, which include DA cells, lead to abnormal feeding behaviors and altered 
metabolism.  
Conclusion: 
Here, we demonstrate that mTORC2 signaling in catecholaminergic 
neurons modulates brain DA homeostasis, and is implicated in DA-related 
behaviors such as novelty-induced hyperlocomotion, hypersensitivity to the 
psychostimulant AMPH, and, importantly, HF diet-specific hyperphagia. 
Importantly, studies in the metabolic chambers (conducted with the support of the 
Mouse Metabolic Phenotyping Center, Vanderbilt) allowed to compare energy 
expenditure, level of activity, oxygen consumption, heat production, and circadian 
rhythms in the TH Rictor KO and control animals (data not shown). This did not 
reveal any differences in basal activity or locomotion between genotypes, 
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suggesting that the increased high-fat food intake was not caused by the 
elevated activity of the TH Rictor mice. Our data support a model in which 
disrupted mTORC2 signaling within catecholaminergic neurons creates aberrant 
striatal DA neurotransmission, and causes HF diet-specific exaggerated 
hyperphagia. These data suggest that mTORC2 signaling defects localized to the 
catecholaminergic pathways are capable of overriding homeostatic circuits, and 
drives aberrant DA-dependent behaviors. 
 
Materials and methods 
 
All procedures were performed according to Vanderbilt University Institutional 
Animal Care and Use Committee approved procedures. 
 
Experimental animals: generation and care 
Mice were engineered as previously described (Siuta et al., 2010; 
Saunders et al., 2014; Dadalko et al., 2015). Briefly, C57Bl6 mice with floxed 
Rictor alleles were crossed to TH-Cre transgenic animals to produce TH-cell 
specific Rictor knockout (TH Rictor KO) mice. Control mice (CTR) were 
littermates that lacked the floxed Rictor allele. To genotype the animals, DNA 
from tail clippings was analyzed by PCR with primers for the floxed, Cre 
recombinase, and recombined alleles as previously described (Shiota et al., 
2006). Male mice were studied from 8 to 18 weeks of age. Mice were housed in a 
temperature (22 °C) and light (12 h light/dark cycle) controlled room with free 
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access to standard laboratory rodent chow diet (#5001, LabDiet; St. Louis, MO) 
and water except where indicated. 
 
Food intake and body composition analysis 
 Mice (male, 8-12 weeks old) were housed individually; diets (Research 
Diets, Inc., NJ, USA: high fat (HF) product number D12492; low fat (LF) product 
number D12450) were randomly assigned. Body weight was determined once 
per week, on a standard balance. Body composition was measured by nuclear 
magnetic resonance (NMR) in a Bruker Body Composition Analyzer (Bruker 
Optics; Billerica, MA). Adiposity (% body fat) was calculated as ((fat mass/lean 
mass)×100). Caloric intake (kcal) was determined daily for the first seven days 
of diet administration and weekly thereafter. Feed efficiency is the ratio of weight 
gained (total body weight, fat and lean), divided by calories consumed (kcal) over 
the indicated period. 
 
Tissue harvest. Monoamine and their metabolites tissue content  
Mice (male, 8-12 weeks old) were sacrificed by rapid decapitation under 
volatile isoflurane anesthesia, brains were removed and chilled on ice. Dorsal 
striatum was dissected out from two hemispheres to create comparable samples 
for both monoamine content and immunoblotting. After dissection, tissue was 
frozen on dry ice and stored in -80°C until use. Monoamine content was 
determined at the Vanderbilt University Neurochemistry Core via high 
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performance liquid chromatography (HPLC) with amperometric detection as 
described previously (Robertson et al., 2010).  
 
Locomotor behavior 
Male mice (8–12 weeks old), were housed in temperature and humidity 
controlled rooms and kept on a 12-h light/dark cycle. Food and water were 
available ad libitum. Experiments were conducted in accordance with the NIH 
guidelines for the care and use of animals and were approved by the Vanderbilt 
University Institutional Animal Care and Use Committee. Initial handling lasted 5 
days, with daily i.p. saline injections. On day 6 mice were tested for open field 
locomotor activity. Four-hour long sessions were performed using automated 
experimental chambers (27.9×27.9 cm; MED-OFA-510; MED Associates, 
Georgia, VT) under constant illumination in a sound-attenuated room. During 
days 7-12 mice were habituated to the chambers and saline injections: four-hour 
sessions with two saline injections daily (at times -120 min and 0 min). On day 
13, mice were injected with saline at time -120 min and allowed to explore the 
chambers for two hours to settle to comparable baseline. At time 0 min, drugs or 
vehicle (saline) were administered i.p. (AMPH 2mg/kg) and locomotion recorded 
for the next two hours. Analysis of open field activity, as well as stereotypic 
counts was performed using Activity Monitor (MED Associates).  
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Statistical analysis 
All data are expressed as the mean ± SEM. Mean differences between 
groups were determined using Student’s t test or one- or two-way ANOVAs 
followed by post hoc testing when the main effect or interaction was significant at 
p < 0.05. Statistical analyses were conducted using GraphPad Prism. The 
number of animals and specific statistical analyses used in each experiment are 
indicated in the figure legends and/or text. 
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CHAPTER IV 
 
DISCUSSION 	  
 Diseases stemming from aberrant peripheral insulin signaling, such as 
obesity and metabolic impairment, are becoming alarmingly common in the 
United States today. According to NIH health surveys, 68.8% of US adults are 
overweight, and 35.7% are obese with body mass index (BMI) above 30. The 
statistics are even more disconcerting for children and adolescents – one third of 
all young people aged 2 to 19 are overweight or obese. Therefore, the 
comorbidity of obesity and mental illness is an important public health concern. 
The first observations of such comorbidity became apparent two centuries ago. 
Sir Henry Maudsley, a pioneering British psychiatrist, wrote, “Diabetes is a 
disease which often shows itself in families in which insanity prevails.” (1868, The 
Physiology and Pathology of Mind”). While it might not seem surprising to 
understand that obesity and/or diabetes may trigger CNS disorders due to 
inflammation and altered vasculature permeability (Gavard et al., 1993; Anderson 
et al., 2001; Lustman et al., 2005; Anderson et al., 2007), emerging literature 
supports peripheral metabolic disorders often preceding psychiatric diagnoses by 
a few years (Mukherjee et al., 1989; Mukherjee et al., 1996; Ryan et al., 2003).  
 Disorders caused by insulin signaling impairment have been extensively 
studied in the periphery, where they lead to obesity and diabetes, which, in turn, 
are linked to the wide-spread life-threatening diseases such as heart disease, 
	   88	  
stroke, and certain types of breast, kidney, colon, and endometrial cancers 
(niddk.nih.gov). In the last decade, impaired peripheral insulin signaling and, 
stemming from it, altered Act activity, were also found to result in aberrant brain 
monoamine neurotransmission (Sevak et al., 2007; Williams et al., 2007; 
Robertson et al., 2010; Owens et al., 2012). Important to note is that brain insulin 
levels depend on the active saturated transport of peripheral insulin across the 
blood brain barrier. This enables peripheral insulin to control central insulin/Akt 
signaling (Banks, 2004). Such vital brain functions as neurodevelopment, 
neurotransmitter release and reuptake, and neuronal receptor trafficking were 
shown to depend on central insulin/Akt signaling (van der Heide et al., 2006). 
Particularly important for this work is that brain DA neurotransmission was found 
to rely on central insulin/Akt signaling (Siuta et al., 2010; Daws et al., 2011; 
Speed et al., 2011; Dadalko et al., 2015). Human epidemiologic data as well as 
studies in animal models showed that aberrant Akt activity is linked to 
monoamine related neuropsychiatric disorders, particularly DA-associated brain 
dysfunctions, which manifest in many mental diseases including schizophrenia 
(Emamian et al., 2004; Siuta et al., 2010), drug addiction (Mazei-Robison et al., 
2011; Neasta et al., 2011; Chen et al., 2012; Collo et al., 2012), and bipolar 
disorder (Beaulieu et al., 2007; Beaulieu et al., 2008; Beaulieu et al., 2009). Of 
utmost interest and relevance to this thesis was to elucidate how fine-tuning of 
Akt activity, particularly its upstream mTORC2/rictor signaling, regulates striatal 
DA homeostasis and subcortical DA-dependent behaviors. Therefore, the 
specific aims of this project were to:  
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I) To test the hypothesis that impairment in brain mTORC2/rictor 
signaling disrupts central DA tone and assess the key elements 
responsible for aberrant striatal DA homeostasis in the nRictor KO 
mice. 
II) To determine whether aberrant brain mTORC2/rictor signaling alters 
DA (subcortical) related behaviors.  
 
III) To assess which neuronal populations or subcortical loci are 
vulnerable to disruption of mTORC2/rictor signaling in producing 
biochemical and behavioral DA-dependent phenotypes.  
 
 Collectively, our studies reveal that disrupted central mTORC2/Akt signaling 
results in aberrant subcortical DA neurotransmission and disrupted DA-
dependent behaviors. We utilized transgenic mouse models and viral intervention 
techniques to induce whole brain or region-specific deletion of protein rictor, an 
essential mTORC2 component. As discussed in Chapter I, mTORC2 is an AGC 
kinase, necessary to phosphorylate Akt at Ser-473. Here, we demonstrate how 
deletion of rictor and the consequential reduction of pAkt-473 in the brain result in 
altered striatal DA tone. Rictor deletion in the nestin-expressing cells as it occurs 
in the nRictor KO mouse was mechanistically supported by both pre- and post-
synaptic changes in the DA system. Thus, nRictor KO mice exhibit diminished 
striatal DA bioavailability and increased DAT expression along with an elevation 
in D2R and its downstream signaling.  
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 Striatal DA neurotransmission is tightly linked to the open field locomotor 
behavior and to the psychomotor response to AMPH (Fahn et al., 1971; Davis et 
al., 1991b; Lotharius and Brundin, 2002; Howes and Kapur, 2009). In line with 
these data, we have found that the biochemical and neurochemical phenotype of 
nRictor KO mice manifests in exaggerated novelty- and AMPH-induced 
locomotor activity. These two hyperactive behaviors have previously been 
associated with increased striatal DA tone (Giros et al., 1996; Gainetdinov et al., 
1999b), which is contrary to our observations in our mouse model with reduced 
striatal DA content and decreased TH Ser-31 phosphorylation (Chapter II). 
Importantly, we have also shown that conditional deletion of rictor in the dorsal 
striatum (via viral intervention) or in the TH-expressing cells (TH Rictor KO 
transgenic mouse model) caused exaggerated AMPH-induced hyperactivity in 
mice. Of interest, TH Rictor KO mice show decreased DA tissue levels in the 
dorsal striatum, exhibiting a similar but less pronounced phenotype to the nRictor 
KO animals. This suggests that low DA tone may result from the disrupted 
mTORC2/rictor signaling in the presynaptic circuitry. This hypothesis is 
supported by the data from virally treated mice, with conditional deletion of rictor 
in the dorsal striatum: these animals do not show significant changes in the 
striatal DA content (data not shown). In addition to the total brain rictor knockout 
and the TH-specific rictor KO, we engineered Dlx5.6 and Nkx2.1 rictor KO mice, 
where deletion of rictor was targeted mostly to the projection neurons of the 
dorsal striatum (Dlx5.6), or mostly to the striatal interneurons (Nkx2.1). These 
animals exhibited no change in biochemical, neurochemical or behavioral 
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phenotypes as pertinent to striatal DA neurotransmission. This suggests that the 
behavioral phenotype of brain rictor deletion may result from a combination of 
altered mTORC2/rictor signaling in the presynaptic and projection striatal 
systems. Our data support the idea that the hyperactive behavior, usually 
ascribed to a hyperdopaminergic state, can be produced with low subcortical DA 
content.  
 Recent studies from our laboratory as well as others show that central DA 
tone depends on intact mTORC2/rictor signaling (Daws et al., 2011). Indeed, 
inhibition of the mTORC2 upstream activator IRS-2 in the VTA caused a 
decrease in the electrically-evoked DA release in the NAc. Furthermore, 
conditional knockout of rictor in the VTA significantly alters the size and 
excitability of the DA neurons, and reduces rewarding responses to morphine 
(Mazei-Robison et al., 2011). In addition, genetic deletion of rictor in the brain 
results in cortical hypodopaminergia, supporting pre-pulse inhibition (PPI) deficits 
in the transgenic mice (Siuta et al., 2010). As discussed in Chapter I, 
mTORC2/rictor/Akt signaling is implicated in the TH neuron survival. Importantly, 
the number of the TH-positive cells in the VTA and SNc was not altered in mice 
that lack neuronal rictor (Siuta et al., 2010). However, we found that DA neuron 
soma size was decreased in the VTA and unaltered in the SNc in the nRictor KO 
mice (Dr. Stanwood, personal communication). With these data in mind, it was 
especially interesting to find significant alterations in the striatal DA tone of the 
nRictor KO mice (Dadalko et al., 2015). These data suggest that mTORC2/rictor 
signaling engages different mechanisms to influence central DA 
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neurotransmission in a region-specific manner. Future investigations are 
warranted to analyze and compare the electrophysiological properties of the VTA 
and SNc DA neurons with aberrant mTORC2/rictor signaling. Additionally, rescue 
experiments employing viral interventions could be employed to tease apart 
which distinct pathways of the dopaminergic neurons in the VTA and SNc drive 
the phenotype.  
 DA homeostasis in the brain is supported by the availability and function of 
monoamine transporters. Compared to the cortical brain regions, where DA tone 
is regulated by the NET (Gresch et al., 1995; Yamamoto and Novotney, 1998; 
Miner et al., 2003; Siuta et al., 2010), in the dorsal striatum, it is the DAT that 
controls DA bioavailability (Giros et al., 1996; Jones et al., 1998). In the nRictor 
mice, striatal tissue DA content is low, whereas DAT expression and function are 
elevated compared to their wild-type counterparts. The Palmiter group showed 
that neonatal DA depletion from DA neurons did not change the expression of 
DAT (Zhou and Palmiter, 1995), suggesting that scarcity of DA would not change 
the levels of the DAT. Conversely, DAT expression and function determine DA 
synaptic bioavailability, as shown in studies of DAT-KO and DAT overexpression 
mice (Giros et al., 1996; Jones et al., 1998; Marazziti et al., 2004; Marazziti et al., 
2007; Salahpour et al., 2008). DAT trafficking and expression is regulated by the 
insulin signaling, particularly by its downstream kinase Akt (Garcia et al., 2005; 
Speed et al., 2010; Speed et al., 2011). Since mTORC2/rictor signaling regulates 
Akt activity (Sarbassov et al., 2005; Franke, 2008b, a), these data suggest a 
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possible pathway that may be implicated in driving DAT overexpression in low 
tissue DA content that we observed in the nRictor KO mice. 
 DAT expression and function are significantly elevated in the dorsal striatum 
of the nRictor KO mice, with disrupted mTORC2/rictor/Akt signaling (Dadalko et 
al., 2015). Previous studies in our laboratory show that downregulation of Akt 
phosphorylation at Thr308, as well as full pharmacologic blockade of Akt by 
allosteric inhibitors (Lindsley et al., 2005; Speed et al., 2010; Speed et al., 2011) 
causes a reduction of DAT surface expression in the dorsal striatum. As 
discussed, nRictor KO mice show the opposite phenotype for DAT. This may be 
supported, at least in part, by an increase in pAkt308 (Appendix Figure 1), which 
exists simultaneously with the reduction of pAkt473 (Dadalko et al., 2015) in the 
dorsal striatum of the KO mice. Supporting an increase in pAkt308 
phosphorylation, we show elevated pGSK3β in the dorsal striatum of nRictor KO 
mice (Appendix Figure 1). It is also possible that another AGC family kinase, 
downstream of mTORC2/rictor signaling, is involved in driving the nRictor KO 
increased DAT phenotype. For example, the AGC family contains 60 members 
(reviewed in (Pearce et al., 2010)), including, PKC and PKA, two kinases heavily 
involved in DAT trafficking, biomechanics, and function regulation (Pristupa et al., 
1998; Blakely and Bauman, 2000; Chang et al., 2001; Granas et al., 2003; 
Khoshbouei et al., 2004; Page et al., 2004). Further studies are needed to tease 
apart how various brain regions employ mTORC2/rictor signaling and differential 
Akt phosphorylation to orchestrate DA homeostasis. 
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 In addition to regulating DAT trafficking and function, Akt activity plays an 
important role in DA receptor signaling. For example, prolonged stimulation of 
D2R causes specific dephosphorylation of Akt at Thr308 (Beaulieu et al., 2004). 
Interestingly, phosphorylation of Akt at its second key residue Ser473 is not 
affected (Beaulieu et al., 2004). Furthermore, depletion of striatal DA in the 
hyperdopaminergic DAT-KO mice or haloperidol induced D2R blockade resulted 
in enhanced phosphorylation of Akt at Thr308, indicating that D2R are 
responsible for the regulation of Akt by DA (Beaulieu et al., 2004; Emamian et al., 
2004). Importantly, Akt Thr308 residue is not directly dependent on 
mTORC2/rictor activity (Sarbassov et al., 2005; Franke, 2008b). This 
underscores the significance and novelty of our finding that D2R, as well as their 
downstream signaling pathways, are increased in the dorsal striatum of nRictor 
KO mice with aberrant mTORC2/rictor signaling and depleted Akt Ser473 
phosphorylation.  
 As discussed above, DA levels do not control the expression of DAT, 
however, DA availability dictates the sensitivity and responsiveness of DA 
receptors. Thus, DA deficient mice reveal oversensitivity of DA receptors without 
exhibiting a change in receptor expression, manifested by an exaggerated 
psychomotor response and c-fos immunoreactivity to DA agonists (Kim et al., 
2000). Importantly, nRictor KO mice demonstrate behaviors (i.e., increased 
novelty-induced hyperlocomotion, AMPH hypersensitivity) traditionally associated 
with elevated DA tone, which is contrary to what we find in nRictor KO mice. 
Hence, we hypothesized that postsynaptic DA receptor signaling is altered in the 
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nRictor KO. In the nRictor KO mice, we show elevated D2R in the dorsal 
striatum. Haloperidol administration confirmed our hypothesis by alleviating 
AMPH-induced hyperactivity and reducing pERK (Chapeter II) and pAkt308 to 
control levels (Appendix Figure 2) in nRictor KO mice. Similarly, in DA deficient 
mice, a mixture of D1-D2 receptor antagonists inhibited the hyperactivity caused 
by the DA agonists (Szczypka et al., 1999). 
D2R may signal via a G-protein coupled pathway, or employ non-
conventional signaling by forming a complex with β-arrestin, Akt, and PP2A 
(Beaulieu et al., 2011). Another mechanism that may be utilized to control D2R 
signaling is MDM2/β-arrestin mediated D2R internalization and its subsequent 
lysosomal degradation. Similar pathway has been previously shown in trafficking 
and degradation of beta2-adrenergic receptors (Shenoy et al., 2001). MDM2, E3 
ubiquitin ligase for β-arrestin, requires phosphorylation by Akt for its activity 
(Milne et al., 2004; Fenouille et al., 2011). In the nRictor KO mice with aberrant 
mTORC2/rictor signaling, the activity of MDM2 may be decreased due to the 
impaired Akt function. Thus, a decrease in β-arrestin mediated D2R 
internalization may be expected. We have shown an increase in D2R expression 
and function in nRictor KO mice. Recently, we have also found that β-arrestin is 
elevated in the dorsal striatum of nRictor KO mice (Appendix Figure 3). 
Assessing the expression of MDM2 and its phosphorylation state is complicated 
by the fact that MDM2 is rapidly cleaved at the DVPD site by Caspase-2, which 
inhibits MDM2 E3 ubiquitin ligase activity (Oliver et al., 2011). Our preliminary 
data demonstrates downregulation of MDM2 in the dorsal striatum of nRictor KO 
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mice (Appendix Figure 4). Further immunoprecipitation experiments, along with 
biochemical assessment of MDM2 phosphorylation, will eventually help elucidate 
this paradigm.  
 Our findings with regard to aberrant central DA signaling in the nRictor KO 
mice are intriguing for several reasons. Besides offering many insights about the 
mechanisms of DA-dependent neuropsychiatric phenotypes, this mouse model 
provides a broad platform for studying central regulation of peripheral 
neuroendocrinology and metabolism. As discussed above, brain DA signaling 
and mTORC2/rictor/Akt pathway are underlying the interdependent mechanism 
implicated in the well-established comorbid nature of metabolic impairments and 
DA-related neuropsychiatric disorders. nRictor KO is a great model to explore the 
specific pathways that drive such comorbidity. Indeed, nRictor KO mice combine 
neuropsychiatric-like endophenotypes as well as metabolic abnormalities: cortical 
hypodopaminergia, aberrant subcortical DA neurotransmission, and altered DA-
dependent behaviors (Siuta et al., 2010; Dadalko et al., 2015), as well as insulin 
resistance, impaired glucose utilization, hyperphagia and obesity (Kocalis et al., 
2014). These data emphasize that aberrant central mTORC2/rictor signaling 
heavily impacts peripheral metabolic regulation.  
 In the last decade, significant attention has been devoted to isolating 
homeostatic and hedonic regulators that control energy balance and metabolism 
(Blundell et al., 2000; Castro et al., 2015). Hypothalamic homeostatic 
mechanisms are in place to match energy expenditure with appropriate calorie 
consumption. However, brain circuitry responsible for sensing and predicting 
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reward and salience for palatable diet may override homeostatic mechanisms, 
resulting in overconsumption and metabolic impairment. Accumulating evidence 
from clinical studies and animal models shows that brain circuits supporting 
substance abuse behaviors are implicated in “food addiction” (Johnson and 
Kenny, 2010; Kenny, 2011, 2013; Volkow et al., 2013; Tomasi et al., 2015). After 
seeing the robust metabolic phenotype in the nRictor KO mice, we became 
interested to explore how extensive the reward/salience neurocircuitry is in 
producing such severe metabolic imbalance. We began by engineering a mouse 
model with aberrant mTORC2/rictor singling in the TH expressing neurons: TH 
Rictor KO mice. 
 TH Rictor KO mice exhibit exaggerated overconsumption of high-fat (60% 
fat) diet. Our data strongly support a link between disrupted catecholaminergic 
mTORC2/rictor signaling and high-fat induced hyperphagia (Dadalko et al, in 
press). Hence, for the first time, we show that the mice with a deletion of rictor in 
the catecholaminergic neurons are extremely hyperphagic only on a palatable, 
high-fat diet, which makes them obese at much faster rates compared to their 
wild-type counterparts fed the same diet. It should be noted that the TH Rictor 
KO mice maintain normal food consumption and exhibit no obesity phenotype 
while on regular or low-fat chow (Dadalko et al, in press). Of interest, we also 
assessed the food intake of mice that lack rictor in the Dlx and Nkx expressing 
neurons, finding no difference in their consumption of high-fat food relative to the 
control wild-type mice (data not shown). Moreover, viral transgene-mediated 
deletion of rictor in the dorsal striatum has not produced either similar feeding 
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phenotype or metabolic abnormalities, despite causing AMPH-induced 
hypersensitivity. These data highlight the importance of intact mTORC2/rictor 
signaling within catecholaminergic neurons to maintain the integrity of high-fat 
food feeding. Future studies employing viral intervention techniques and 
metabolic chambers will help to pinpoint the neurocircuits responsible for 
obscuring the homeostatic energy balance. Specifically, condition place 
preference tests with highly palatable food and drugs of abuse will also help 
elucidate the mechanisms involved in the convergence of neuroendocrinology 
with the neurobiology of substance abuse disorders.  
 Similar to the nRictor KO, the VTA DA neurons of the TH Rictor KO animals 
have decreased soma size (Dr. Horvath, personal communication). This 
phenotype has been implicated in abnormal reward for morphine  (Mazei-
Robison et al., 2011), and is predicted not to impact the rewarding properties of 
ethanol, cocaine or nicotine (Mazei-Robison et al., 2014). These data suggest a 
pathway linking the soma size of the VTA DA neurons to the mechanism that 
drives higher tolerance for the rewarding properties of morphine, a µ-opioid 
receptor-specific drug. Importantly, high-fat food has been shown to induce a 
quick spike in CSF β-endorphin, an endogenous opioid acting on µ-opioid 
receptor (Mizushige et al., 2006; Mizushige et al., 2009). Additionally, stimulation 
of µ-opioid receptors in the NAc has been shown to stimulate feeding through 
reward-related mechanisms (Baldo et al., 2013; Richard et al., 2013). Further 
exploration of this hypothesis will allow to understand if the aberrant 
mTORC2/rictor within the VTA DA neurons disrupts the ability of DA to properly 
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regulate central β-endorphin levels (Deutch and Martin, 1983), leading to the 
increased tolerance for the rewarding properties of the high-fat food and 
consequentially to the exaggerated escalating consumption of high-fat diet as it 
occurs in the TH Rictor KO mice.  
 In conclusion, the data presented here enhances the understanding of how 
metabolic signaling via mTORC2/rictor can influence central DA homeostasis 
and reveals that mTORC2/rictor pathway is a pivotal regulator of subcortical DA 
neurotransmission, AMPH action, and high-fat food intake. Our data also support 
the fact that dysfunction of mTORC2/rictor signaling in the brain may be a 
possible mechanism underlying the etiology of schizophrenia and the comorbidity 
of DA-related neuropsychiatric disorders and peripheral metabolic impairments.  
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APPEXDIX 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure 1. Akt-308 and GSK3β phosphorylation in the nRictor KO 
mouse dorsal striatum. (A) Quantification of pAkt308 normalized to total Akt 
(expressed as a percent of control) in the dorsal striatum of control wild type and 
nRictor KO mice. (Student’s t-test, p=0.0002, df=13) (B) Quantification of 
pGSK3β normalized to total GSK3 (shown as a percent of control) dorsal 
striatum of control wild type and nRictor KO mice. (Student’s t-test, p=0.01, 
df=13)  
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Appendix Figure 2. Haloperidol reduces pAkt-308 in the dorsal striatum of 
nRictor KO mice. Acute administration of haloperidol (i.p., 0.8mg/kg) reduced 
expression of pAkt308 in the dorsal striatum of nRictor mice. Shown is 
quantification of immunoblot optical densities. Data obtained from striatal tissue 
of CTR and nRictor mice injected with either vehicle or haloperidol (Haldol). Data 
were normalized to saline injected CTR. (Student’s t-test, p=0.03, df=10) 
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Appendix Figure 3. β-arrestin is elevated in the dorsal striatum of nRictor 
KO mice. 	  Optical density quantitation (left) and representative immunoblots 
(right) of β-arrestin expression in the dorsal striatum of nRictor KO (Nestin Rictor 
KO) and control wild type (Wild Type) animals. Actin was probed as a loading 
control. Data are expressed as percent of control. (Student’s t-test, p=0.01, 
df=13[1])  
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Appendix Figure 4. MDM2 is decreased in the dorsal striatum of nRictor KO 
mice. Optical density quantitation (left) and representative immunoblots (right) of 
MDM2 expression in the dorsal striatum of nRictor KO (Nestin Rictor KO) and 
control wild type (WT) animals. Actin was probed as a loading control. Data are 
expressed as percent of control. (Student’s t-test, p=0.02, df=12[2]) 
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